Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies, and methods of using anti-HLA-G antibodies

Abstract

Provided herein are antibodies that selectively bind to HLA-G and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Description

[0001] This application is a divisional application of the invention patent application with application number 201980074775.4, filed on September 26, 2019, entitled "Anti-HLA-G antibody, composition containing anti-HLA-G antibody and method of using anti-HLA-G antibody", which entered the national phase in China.

[0002] Related applications

[0003] This application claims priority to U.S. Provisional Application No. 62 / 737,666, filed on September 27, 2018, which is incorporated herein by reference in its entirety. Technical Field

[0004] This document provides antibodies with HLA-G binding specificity and compositions comprising said antibodies, including pharmaceutical compositions, diagnostic compositions, and kits. Methods for using anti-HLA-G antibodies for therapeutic and diagnostic purposes are also provided. Background Technology

[0005] HLA-G, a type I histocompatibility antigen (also known as human leukocyte antigen G (HLA-G)), is a protein encoded by the HLA-G gene in humans. HLA-G belongs to the non-classical class I heavy chain paralogs of HLA. HLA-G is a heterodimer (β-2 microglobulin) composed of heavy and light chains. HLA-G exists in membrane-bound and soluble forms.

[0006] HLA-G is typically expressed at the maternal-fetal interface and other immune-privileged sites. HLA-G may play a role in immune tolerance during pregnancy, being expressed in the placenta by extravillous trophoblast cells, unlike classic MHC class I genes (HLA-A and HLA-B). Since HLA-G was first identified in placental samples, numerous studies have evaluated its role in pregnancy disorders such as preeclampsia and recurrent pregnancy loss. See Michita, Rafael Tomoya, et al., Human Immunology. 2016, 77(10):892-897, which is incorporated herein by reference in its entirety (including any figures).

[0007] HLA-G has been shown to be immunosuppressive. By binding to receptors expressed on various myeloid and lymphoid cells, HLA-G can directly inhibit the function of NK cells, cytotoxic T lymphocytes, B cells, neutrophils, monocytes, macrophages, and dendritic cells. HLA-G also inhibits the proliferation of T cells and NK cells, as well as their cytolytic activity. HLA-G inhibits phagocytosis and induces the production or expansion of regulatory T cells.

[0008] HLA-G mediates immune function through at least three ITIM-containing inhibitory receptors (ILT2, ILT4, and KIR2DL4). For example, on lymphoid and myeloid cells, HLA-G functions via ILT2. On myeloid cells, HLA-G functions via ILT4. On decidual NK cells, HLA-G mediates immune function via both KIR2DL4 and ILT2.

[0009] HLA-G is an immune checkpoint target. HLA-G can directly inhibit immune cell function through receptor binding and / or trogocytosis and chemotactic impairment. HLA-G can confer a higher invasive and metastatic potential on tumor cells. HLA-G promotes the evasion of tumor immune surveillance and enhances the metastasis and progression of malignant tumors. During tumor progression, HLA-G has other roles, such as inhibiting immune cell cytolysis, inducing immune cell apoptosis, and / or generating regulatory cells through receptor binding and / or trogocytosis.

[0010] HLA-G expression is upregulated in a wide range of tumors and is associated with poor prognosis and disease progression. Serum HLA-G levels are elevated in breast cancer, lung cancer, colorectal cancer (CRC), gastric cancer, esophageal cancer, neuroblastoma, cervical cancer, and hematologic malignancies. HLA-G has also been found to be associated with clinical parameters in advanced disease, such as tumor metastasis, poor prognosis, immune evasion, and tumor invasiveness.

[0011] HLA-G is an attractive target for diseases such as, for example, cancer. Summary of the Invention

[0012] This document provides antibodies that selectively bind to HLA-G. In some embodiments, the antibody binds to human HLA-G. In some embodiments, the antibody comprises at least one CDR sequence defined by a common sequence provided in this disclosure. In some embodiments, the antibody comprises an exemplary CDR, V, provided in this disclosure. H or V L One or more of the sequence or its variants. In some respects, the variant is a variant having one or more conserved amino acid substitutions.

[0013] Compositions and kits containing the antibodies are also provided. In some embodiments, the composition is a pharmaceutical composition. Any suitable pharmaceutical composition can be used. In some embodiments, the pharmaceutical composition is a composition for parenteral administration.

[0014] This disclosure also provides methods for using the anti-HLA-G antibodies provided herein. In some embodiments, the methods are therapeutic methods. In some embodiments, the methods are analytical methods. In some embodiments, the methods are methods for purifying and / or quantifying HLA-G.

[0015] In some embodiments, the method is a diagnostic method. In some embodiments, the diagnostic method includes detecting HLA-G expressed by a tumor, or consists of detecting HLA-G expressed by a tumor. In some embodiments, the diagnostic method includes detecting soluble HLA-G, or consists of detecting soluble HLA-G. In some embodiments, the detection method includes detecting HLA-G expression on immune cells, or consists of detecting HLA-G expression on immune cells.

[0016] In some embodiments, the antibody is used to treat a disease or condition. In some aspects, the disease or condition is selected from cancer, autoimmune diseases, and infections. Some aspects provide for the use of any antibody or pharmaceutical composition provided herein for the treatment of a disease or condition selected from cancer, autoimmune diseases, and infections.

[0017] Brief description of the attached diagram

[0018] Figure 1 A table showing the affinity and monomer affinity of anti-HLA-G antibodies for recombinant HLA-G proteins is provided.

[0019] Figure 2A and Figure 2B A biolayer interferometry sensor map showing anti-HLA-G antibodies that bind to HLA-G is provided, and they can be divided into three biochemical chambers based on their ability to cross-block each other when tested in pairs for binding.

[0020] Figure 3 A biolayer interferometry sensor map is provided, showing antibodies that bind to HLA-G at different levels of effectiveness and block the interaction of HLA-G with ILT2 and ILT4.

[0021] Figure 4 Evaluation of anti-HLA-G antibodies that bind to naturally expressed HLA-G found on JEG-3 tumor cells is shown.

[0022] Figure 5A , Figure 5B , Figure 5C and Figure 5D Data are provided for Fab and antibody against HLA-G that restore NKL killing activity by blocking inhibition mediated by the interaction of HLA-G with ILT2 or ILT4.

[0023] Figure 6 provides an evaluation of how anti-HLA-G antibodies reverse HLA-G-mediated inhibition of primary human cells. Figure 6A and Figure 6B It provides an evaluation of phagocytosis in human macrophage assays. Figure 6C An evaluation of the cytotoxic activity of primary human NK cells was provided. Figure 6D It provides an evaluation of the function of primary human CD8+ T cells.

[0024] Figure 7A and Figure 7B The results show the binding values ​​of the anti-HLA-G antibody to a single recombinant HLA class Ia antigen immobilized on the beads.

[0025] Figure 8 Evaluation of anti-HLA-G antibodies bound to a group of 28 HLA subtypes B-LCL lineages is shown.

[0026] Figure 9A and Figure 9B Evaluation of anti-HLA-G antibodies that bind to various forms of HLA-G after site-directed mutagenesis is presented.

[0027] Figure 10 This study provides evidence of the inhibitory effect of anti-HLA-G antibodies with Fc effector function on tumor growth in a mouse tumor xenograft model using HLA-G-expressing 721.221 cells. Detailed Implementation

[0028] 1. Definition

[0029] Unless otherwise defined, all technical terms, symbols, and other scientific terms used herein are intended to have the meaning commonly understood by one of ordinary skill in the art to which this invention pertains. In some instances, for clarity and / or ease of reference, terms having a commonly understood meaning are defined herein, and such definitions are not necessarily construed as representing a difference from the commonly understood meaning in the art. The techniques and procedures described or referenced herein are generally well understood and commonly used by those skilled in the art using conventional methods (such as, for example, the widely used molecular cloning methods described in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Where appropriate, unless otherwise stated, procedures involving the use of commercially available kits and reagents are generally performed according to the manufacturer's prescribed protocols and / or parameters.

[0030] Unless the context clearly indicates otherwise, the singular forms “a (a, an)” and “the” used herein include plural indicators.

[0031] The term "about" indicates and covers the indicated value as well as the range above and below that value. In some embodiments, the term "about" indicates a specified value ±10%, ±5%, or ±1%. In some embodiments, the term "about" indicates a specified value ± one standard deviation of that value.

[0032] The term "the combination thereof" includes every possible combination of the elements referred to by the term.

[0033] The term "immunoglobulin" refers to a class of structurally related proteins that typically consist of two pairs of polypeptide chains: a pair of light (L) chains and a pair of heavy (H) chains. In a "complete immunoglobulin," all four chains are linked together by disulfide bonds. The structure of immunoglobulins has been well characterized. See, for example, Paul, Fundamental Immunology, 7th Edition, Ch. 5 (2013), Lippincott, Williams & Wilkins, Philadelphia, PA. Simply put, each heavy chain typically contains a heavy chain variable region (V... H ) and heavy chain constant region (C H Heavy chain constant regions typically contain three structural domains (C). H1 C H2 and C H3 Each light chain typically contains a light chain variable region (V). LThe light chain constant region typically contains a structural domain (abbreviated as CL).

[0034] The term "antibody" describes a class of immunoglobulin molecules and is used herein in its broadest sense. Antibodies specifically include complete antibodies (e.g., complete immunoglobulins), as well as antibody fragments and antigen-binding proteins. Antibodies include at least one antigen-binding domain. An example of an antigen-binding domain is formed by V... H -V L The antigen-binding domain formed by the dimer. "HLA-G antibody", "anti-HLA-G antibody", "HLA-G Ab", "HLA-G specific antibody" or "anti-HLA-GAb" are antibodies that specifically bind to the antigen HLA-G as described herein.

[0035] V H District and V L The regions can be further subdivided into hypervariable regions (“HVR”; also known as complementarity-determining regions (CDR)), which alternate with more conservative regions. The more conservative regions are called framing regions (FR). Each V H and V L It typically contains three CDRs and four FRs arranged in the following order (from N-terminus to C-terminus): FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. CDRs participate in antigen binding and confer antigen specificity and binding affinity to antibodies. See Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition (1991), Public Health Service, National Institutes of Health, Bethesda, MD, which is incorporated herein by reference in its entirety.

[0036] Light chains from any vertebrate species can be classified into one of two types (called κ and λ) based on the sequence of constant structural domains.

[0037] Heavy chains from any vertebrate species can be classified into one of five distinct classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also named α, δ, ε, γ, and μ, respectively. IgG and IgA classes are further subdivided based on sequence and functional differences. Humans express the following subclasses: IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0038] The amino acid sequence boundaries of a CDR can be determined by those skilled in the art using any of a variety of known numbering schemes, including Kabat et al. (“Kabat” numbering scheme); Al-Lazikani et al., 1997, J.Mol.Biol., 273:927-948 (“Chothia” numbering scheme); MacCallum et al., 1996, J.Mol.Biol. 262:732-745 (“Contact” numbering scheme); Lefranc et al., Dev.Comp.Immunol., 2003, 27:55-77 (“IMGT” numbering scheme); and Honegge and Plückthun, J.Mol.Biol., 2001, 309:657-70 (“AHo” numbering scheme), each of which is incorporated herein by reference in its entirety.

[0039] Table 1 provides the locations of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3, as identified by the Kabat and Chothia schemes. For CDR-H1, both the Kabat and Chothia numbering schemes are used to provide residue numbering.

[0040] Unless otherwise stated, the numbering scheme used to identify a specific CDR in this document is the Kabat / Chothia numbering scheme. When the residues covered by these two numbering schemes differ, either the Kabat or Chothia numbering scheme shall be specified.

[0041] Table 1. Residues in the CDR according to the Kabat and Chothia numbering scheme.

[0042] CDR Kabat Chothia L1 L24-L34 L24-L34 L2 L50-L56 L50-L56 L3 L89-L97 L89-L97 H1 (Kabat number) H31-H35B H26-H32 or H34* H1 (Chothia designation) H31-H35 H26-H32 H2 H50-H65 H52-H56 H3 H95-H102 H95-H102

[0043] *When using the Kabat numbering convention, the C end of CDR-H1 varies between H32 and H34 depending on the length of the CDR.

[0044] When referring to residues in the constant region of the antibody heavy chain, the “EU numbering scheme” is typically used (e.g., as reported by Kabat et al. (see above)). Unless otherwise stated, the EU numbering scheme is used to refer to residues in the constant region of the antibody heavy chain as described herein.

[0045] "Antibody fragments" include portions of a complete antibody, such as the antigen-binding region or variable region of the complete antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(abˊ)2 fragments, Fabˊ fragments, scFv(sFv) fragments, and scFv-Fc fragments.

[0046] The “Fv” fragment is a non-covalently linked dimer of a heavy chain variable domain and a light chain variable domain.

[0047] In addition to the variable structure domains of the heavy chain and the light chain, the “Fab” fragment also contains the constant structure domain of the light chain and the first constant structure domain (C) of the heavy chain. H1 Fab fragments can be produced, for example, by papain digestion of a full-length antibody.

[0048] The “F(abˊ)2” fragment contains two Fab' fragments linked by disulfide bonds near the hinge region. The f(abˊ)2 fragment can be produced, for example, by pepsin digestion of an intact antibody. The F(abˊ) fragment can be dissociated, for example, by treatment with β-mercaptoethanol.

[0049] "Single-chain Fv" or "sFv" or "scFv" antibody fragments contain V in a single polypeptide chain. H Domain and V L Domain. V H and V L Typically linked via peptide linkers, see Plückthun A. (1994). Antibodies from Escherichia coli. Rosenberg M. & Moore GP (eds.), The Pharmacology of Monoclonal Antibodies, Vol. 113 (pp. 269-315). Springer-Verlag, New York, which is incorporated herein by reference in its entirety. The “scFv-Fc” fragment contains an scFv attached to the Fc domain. For example, the Fc domain may attach to the C-terminus of the scFv. The Fc domain may follow the V... H or V L This depends on the orientation of the variable structural domain in scFv (i.e., V). H -V L or V L -V H Any suitable Fc domain known in the art or described herein may be used.

[0050] The term "monoclonal antibody" refers to an antibody derived from a substantially homogeneous group of antibodies. A substantially homogeneous group of antibodies includes antibodies that are substantially similar and bind one or more of the same epitopes, except for variants that are typically present during the production of monoclonal antibodies. Such variants are usually present only in small amounts. Monoclonal antibodies are typically obtained by a method involving the selection of a single antibody from a variety of antibodies. For example, the selection method may be to choose a unique clone from a library of multiple clones, such as hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody may be further modified, for example, to improve affinity for the target ("affinity maturation"), humanize the antibody, improve its yield in cell cultures, and / or reduce its immunogenicity in subjects.

[0051] The term "chimeric antibody" refers to an antibody in which a portion of the heavy chain and / or light chain is derived from a specific source or species, while the remainder of the heavy chain and / or light chain is derived from a different source or species.

[0052] A “humanized” form of a nonhuman antibody is a chimeric antibody containing a minimal sequence derived from a nonhuman antibody. Humanized antibodies are typically human immunoglobulins (receptor antibodies), in which residues from one or more CDRs are replaced by residues from one or more CDRs from a nonhuman antibody (donor antibody). The donor antibody can be any suitable nonhuman antibody, such as mouse, rat, rabbit, chicken, or nonhuman primate antibodies with the desired specificity, affinity, or biological effect. In some cases, selected frame region residues of the receptor antibody are replaced by corresponding frame region residues from the donor antibody. Humanized antibodies may also contain residues not found in either the receptor or donor antibody. Such modifications can be made to further improve antibody function. For further details, see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332:323-329; and Presta, Curr. Op. Struct. Biol., 1992, 2:593-596, each of which is included in its entirety by citation.

[0053] "Human antibody" is an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human or human cell, or an antibody derived from a non-human source using a human antibody library or a human antibody encoding sequence (e.g., obtained from a human source or designed de novo). Human antibodies do not specifically include humanized antibodies.

[0054] "Isolated antibody" is an antibody that has been isolated and / or recovered from components of its native environment. Components of the native environment may include enzymes, hormones, and other protein or non-protein materials. In some embodiments, the isolated antibody is purified to a degree sufficient to obtain at least 15 residues of the N-terminal sequence or internal amino acid sequence, for example, using a spinning cup sequencer. In some embodiments, the isolated antibody is purified to homogenization by gel electrophoresis (e.g., SDS-PAGE) under reducing or non-reducing conditions and detected by Coomassie blue or silver staining. Isolated antibodies include antibodies in situ within recombinant cells, since at least one component of the antibody's native environment is absent. In some aspects, the isolated antibody is prepared by at least one purification step.

[0055] In some embodiments, the isolated antibody is purified to at least 80 wt%, 85 wt%, 90 wt%, 95 wt%, or 99 wt%. In some embodiments, the isolated antibody is provided in solution form, the solution containing at least 85 wt%, 90 wt%, 95 wt%, 98 wt%, 99 wt%, to 100 wt% antibody, the remainder of which comprises the weight of other solutes dissolved in a solvent.

[0056] “Affinity” refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise stated, “binding affinity” as used herein refers to intrinsic binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of molecule X for its partner Y can generally be determined by the dissociation constant (K). D Affinity can be measured using common methods known in the art, including those described herein. For example, methods such as... The instrument uses surface plasmon resonance (SPR) technology or employs techniques such as... The instrument uses biolayer interferometry to determine affinity.

[0057] Regarding antibody binding to target molecules, the terms "specific binding," "specifically bound to," "specific to," "selectively bound," and "selectively targeted" refer to binding to a specific antigen (e.g., a peptide target) or an epitope on a specific antigen that is measurably distinct from nonspecific or nonselective interactions. Specific binding can be measured, for example, by determining the binding of a molecule against that of a control molecule. Specific binding can also be determined by competition with a control molecule similar to the target (such as an excess of an unlabeled target). In this case, specific binding is indicated if the binding of the labeled target to the probe is competitively inhibited by an excess of the unlabeled target.

[0058] As used in this article, the term "k" d (sec) -1 (Second -1 The term k is the dissociation rate constant for a specific antibody-antigen interaction. This value is also known as k. off value.

[0059] As used in this article, the term "k" a (M) -1 ×sec -1 (Second -1 The association rate constant of a specific antibody-antigen interaction is referred to as k. on value.

[0060] As used in this article, the term "K" D (M) refers to the dissociation equilibrium constant of a specific antibody-antigen interaction. K D =k d / k a .

[0061] As used in this article, the term "K" A (M) -1 K refers to the association equilibrium constant of a specific antibody-antigen interaction. A =k a / k d .

[0062] "Affinity-matured" antibodies refer to antibodies with one or more modifications in one or more CDRs or FRs, said modifications improving the antibody's affinity for its antigen compared to a parent antibody without said one or more modifications. In one embodiment, the affinity-matured antibody has nanomolar or picomolar affinity for the target antigen. Affinity-matured antibodies can be produced using a variety of methods known in the art. For example, Marks et al. (Bio / Technology, 1992, 10:779-783, which are incorporated herein by reference in their entirety) described a method using V... H and V LAffinity maturation of domain shuffling. Random mutagenesis of CDRs and / or framework residues is described in, for example, by Barbas et al. (Proc. Nat. Acad. Sci. USA, 1994, 91: 3809-3813); Schier et al., Gene, 1995, 169: 147-155; Yelton et al., J. Immunol., 1995, 155: 1994-2004; Jackson et al., J. Immunol., 1995, 154: 3310-33199; and Hawkins et al., J. Mol. Biol., 1992, 226: 889-896, each of which is incorporated herein by reference in its entirety.

[0063] When used herein in the context of two or more antibodies, the term "competition" or "cross-competition" refers to two or more antibodies competing for binding to an antigen (e.g., HLA-G). In an exemplary assay, HLA-G is coated onto a plate and bound to a first antibody, followed by the addition of a second labeled antibody. If the presence of the first antibody reduces the binding of the second antibody, then the antibodies compete. The term "competition" also includes combinations of antibodies where one antibody reduces the binding of another antibody, but no competition is observed when the antibodies are added in reverse order. However, in some embodiments, the first and second antibodies inhibit each other's binding regardless of the order in which they are added. In some embodiments, one antibody reduces the binding of another antibody to its antigen by at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

[0064] The term "epitope" refers to a portion of an antigen that can specifically bind to an antibody. Epitopes often consist of surface-accessible amino acid residues and / or sugar side chains, and may possess specific three-dimensional structural features and specific charge characteristics. The difference between conformational and non-conformational epitopes lies in the fact that binding to the former, but not the latter, is lost in the presence of denaturing solvents. Epitopes may contain amino acid residues that directly participate in binding and other amino acid residues that do not directly participate in binding. The epitopes to which antibodies bind can be determined using known epitope identification techniques, such as, for example, testing the binding of antibodies to HLA-G variants with different point mutations.

[0065] The "percentage of identity" between a polypeptide sequence and a reference sequence is defined as the percentage of amino acid residues in the polypeptide sequence that are identical to those in the reference sequence after the sequences have been aligned and vacancies have been introduced (if necessary) to achieve the maximum percentage of sequence identity. Alignments used to determine the percentage of amino acid sequence identity can be performed in various ways within the scope of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, or CLUSTAL OMEGA software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms required to achieve maximum alignment across the entire length of the sequences being compared.

[0066] "Conservative substitution" or "conservative amino acid substitution" refers to the substitution of one or more amino acids by one or more chemically or functionally similar amino acids. Conservative substitutions that provide similar amino acids are well known in the art. Peptide sequences having such substitutions are referred to as "variants of conserved modifications." For example, the following groups of amino acids are considered to be conserved substitutions of each other.

[0067] acid residues D and E basic residues K, R, and H Hydrophilic uncharged residues S, T, N, and Q Aliphatic uncharged residues G, A, V, L and I Nonpolar, uncharged residues C, M, and P Aroma residues F, Y and W

[0068]

[0069]

[0070] Group 1 A, S, and T Group 2 D and E Group 3 N and Q Group 4 R and K Group 5 I, L and M Group 6 F, Y and W

[0071] Group A A and G Group B D and E Group C N and Q Group D R, K and H Group E I, L, M, V Group F F, Y and W Group G S and T Group H C and M

[0072] Other conserved substitutions can be found, for example, in Creighton, Proteins: Structures and Molecular Properties, 2nd Edition (1993), WH Freeman & Co., New York, NY. Antibodies produced by making one or more conserved substitutions to amino acid residues in the parent antibody are called "conserved variants".

[0073] The term "amino acid" refers to 20 naturally occurring amino acids. These include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine ​​(Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).

[0074] In some embodiments, “treating” any disease or condition means improving the disease or condition present in the subject. In another embodiment, “treating” includes improving at least one bodily parameter that the subject may have difficulty identifying. In yet another embodiment, “treating” includes regulating the disease or condition physically (e.g., stabilizing identifiable symptoms) or physiologically (e.g., stabilizing bodily parameters), or both. In yet another embodiment, “treating” includes delaying or preventing the onset of the disease or condition.

[0075] As used herein, the term "therapeutic effective amount" or "effective amount" refers to the amount of an antibody or composition that is effective in treating a disease or condition when administered to a subject.

[0076] As used herein, the term "subject" refers to a mammalian subject. Exemplary subjects include, but are not limited to, humans, monkeys, dogs, cats, mice, rats, cattle, horses, camels, birds, goats, and sheep. In some embodiments, the subject is a human. In some embodiments, the subject suffers from cancer, autoimmune disease or condition, and / or infection that can be treated with the antibodies provided herein. In some embodiments, the subject is a person suspected of having cancer, autoimmune disease or condition, and / or acute and chronic infections.

[0077] 2. Antibodies

[0078] This article provides antibodies that selectively bind to human HLA-G. In some aspects, said antibodies selectively bind to the extracellular domains of human HLA-G.

[0079] In some embodiments, the antibody has one or more CDRs of a specific length (in terms of the number of amino acid residues). In some embodiments, the length of the Chothia CDR-H1 of the antibody is 6, 7, 8, or 9 residues. In some embodiments, the length of the Kabat CDR-H1 of the antibody is 4, 5, 6, or 7 residues. In some embodiments, the length of the Chothia CDR-H2 of the antibody is 5, 6, or 7 residues. In some embodiments, the length of the Kabat CDR-H2 of the antibody is 15, 16, 17, or 18 residues. In some embodiments, the length of the Kabat / Chothia CDR-H3 of the antibody is 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 residues.

[0080] In some aspects, the length of the Kabat / Chothia CDR-L1 of the antibody is 9, 10, 11, 12, 13, 14, 15, or 16 residues. In some aspects, the length of the Kabat / Chothia CDR-L2 of the antibody is 6, 7, or 8 residues. In some aspects, the length of the Kabat / Chothia CDR-L3 of the antibody is 8, 9, 10, 11, or 12 residues.

[0081] In some embodiments, the antibody comprises a light chain. In some aspects, the light chain is a κ light chain. In some aspects, the light chain is a λ light chain.

[0082] In some embodiments, the antibody comprises a heavy chain. In some aspects, the heavy chain is IgA. In some aspects, the heavy chain is IgD. In some aspects, the heavy chain is IgE. In some aspects, the heavy chain is IgG. In some aspects, the heavy chain is IgM. In some aspects, the heavy chain is IgG1. In some aspects, the heavy chain is IgG2. In some aspects, the heavy chain is IgG3. In some aspects, the heavy chain is IgG4. In some aspects, the heavy chain is IgA1. In some aspects, the heavy chain is IgA2.

[0083] In some embodiments, the antibody is an antibody fragment. In some aspects, the antibody fragment is an Fv fragment. In some aspects, the antibody fragment is a Fab fragment. In some aspects, the antibody fragment is an F(abˊ)2 fragment. In some aspects, the antibody fragment is a Fab' fragment. In some aspects, the antibody fragment is an scFv (sFv) fragment. In some aspects, the antibody fragment is an scFv-Fc fragment.

[0084] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody.

[0085] In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody.

[0086] In some embodiments, the antibody is an affinity-matured antibody. In some aspects, the antibody is an affinity-matured antibody derived from the exemplary sequences provided in this disclosure.

[0087] In some embodiments, the antibody blocks the interaction and / or binding of HLA-G with the ITIM inhibitory receptor. In some embodiments, the antibody blocks the interaction and / or binding of HLA-G with ILT2. In some embodiments, the antibody blocks the interaction and / or binding of HLA-G with ILT4. In some embodiments, the antibody blocks the interaction and / or binding of HLA-G with KIR2DL4. In some embodiments, the antibody binds HLA-G but does not block the interaction between HLA-G and ILT2, ILT4, and / or KIRDL4. In some embodiments, the antibody disrupts HLA-G heterodimers and / or prevents HLA-G dimerization.

[0088] In some embodiments, the antibody inhibits immunosuppressive function. In some embodiments, the antibody inhibits HLA-G-mediated suppression of NK cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of cytotoxic T lymphocytes. In some embodiments, the antibody inhibits HLA-G-mediated suppression of B cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of neutrophils. In some embodiments, the antibody inhibits HLA-G-mediated suppression of dendritic cells. In some embodiments, the antibody inhibits HLA-G-mediated suppression of macrophages. In some embodiments, the antibody inhibits HLA-G-mediated suppression of monocytes. In some embodiments, the antibody inhibits HLA-G-mediated suppression of NK and / or T cell cytolysis and / or proliferation.

[0089] In some embodiments, the antibody prevents or inhibits HLA-G-mediated repression of phagocytosis. In some embodiments, the antibody mediates HLA-G-mediated induction of regulatory T cells. In some embodiments, the antibody prevents or inhibits the generation or expansion of regulatory T cells.

[0090] The antibodies provided herein can be used to treat a variety of diseases and conditions, including cancer, autoimmune diseases, and infections. In some embodiments, the antibodies inhibit HLA-G function on tumor cells. In some embodiments, the antibodies inhibit HLA-G function on immune cells. In some embodiments, the antibodies inhibit HLA-G function on myeloid cells. In some embodiments, the antibodies inhibit HLA-G function on T cell subsets. In some embodiments, the antibodies inhibit metastasis. In some embodiments, the antibodies inhibit angiogenesis.

[0091] In some embodiments, the antibody competes with or is capable of competing with another antibody for binding to human HLA-G. In some embodiments, the antibody comprises an antibody capable of competing with a reference antibody for binding to human HLA-G, or consists of an antibody capable of competing with a reference antibody for binding to human HLA-G, wherein the reference antibody binds to the human HLA-G polypeptide containing epitopes at positions 195, 197, and / or 198 of SEQ ID NO: 342. In some embodiments, the antibody and the reference antibody cross-compete with or are capable of cross-competing with another antibody for binding to human HLA-G.

[0092] In some embodiments, the antibody binds to a human HLA-G peptide comprising epitopes at positions 195, 197, and / or 198 of SEQ ID NO:342. In some aspects, the epitope comprises or consists of continuous or discontinuous amino acid spans comprising residues 195, 197, and / or 198 of the sequence described in SEQ ID NO:342. In some aspects, the epitope comprises residues 195, 197, and / or 198 of the sequence described in SEQ ID NO:342. In some aspects, the epitope has a sequence having 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% identity to the sequence described in SEQ ID NO:342. In some aspects, the epitope has 1, 2, 3, 4, 5, 6, 7, 8, or 9 substitutions of sequences from the sequence described in SEQ ID NO:342. In some aspects, the epitope has 1, 2, or 3 substitutions of residues from the sequence described in SEQ ID NO:342. In some aspects, the antibody is contacted with any of the residues listed in Figure 9.

[0093] 2.1. CDR-H3 sequence

[0094] In some embodiments, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising, consisting of, or substantially consisting of sequences selected from SEQ ID NO:76-101. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:76, or substantially consisting of SEQ ID NO:76. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:77, or substantially consisting of SEQ ID NO:77. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:78, or substantially consisting of SEQ ID NO:78. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:79, or consisting of, or substantially consisting of, SEQ ID NO:79. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:80, or consisting of, or substantially consisting of, SEQ ID NO:80. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:81, or consisting of, or substantially consisting of, SEQ ID NO:81. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:82, or consisting of, or substantially consisting of, SEQ ID NO:82. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:83, or consisting of, or substantially consisting of, SEQ ID NO:83. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:84, consisting of, or substantially consisting of SEQ ID NO:84. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:85, consisting of, or substantially consisting of SEQ ID NO:85.In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:86, or consisting essentially of SEQ ID NO:86. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:87, or consisting essentially of SEQ ID NO:87. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:88, or consisting essentially of SEQ ID NO:88. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:89, or consisting essentially of SEQ ID NO:89. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:90, or consisting essentially of SEQ ID NO:90. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:91, consisting of, or substantially consisting of SEQ ID NO:91. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:92, consisting of, or substantially consisting of SEQ ID NO:92. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:93, consisting of, or substantially consisting of SEQ ID NO:93. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:94, consisting of, or substantially consisting of SEQ ID NO:94. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:95, consisting of, or substantially consisting of SEQ ID NO:95. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:96, consisting of, or substantially consisting of SEQ ID NO:96. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:97, consisting of, or substantially consisting of SEQ ID NO:97.In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:98, consisting of, or substantially consisting of SEQ ID NO:98. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:99, consisting of, or substantially consisting of SEQ ID NO:99. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:100, consisting of, or substantially consisting of SEQ ID NO:100. In some aspects, the antibody comprises a CDR-H3 sequence, the CDR-H3 sequence comprising SEQ ID NO:101, consisting of, or substantially consisting of SEQ ID NO:101.

[0095] In some aspects, the CDR-H3 sequence includes variants of the exemplary CDR-H3 sequence provided in this disclosure, consists of variants of the exemplary CDR-H3 sequence provided in this disclosure, or is substantially composed of variants of the exemplary CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence includes sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-H3 sequence provided in this disclosure, consists of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-H3 sequence provided in this disclosure, or is substantially composed of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises any exemplary CDR-H3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, consists of any exemplary CDR-H3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary CDR-H3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0096] 2.2. V containing exemplary CDRs H sequence

[0097] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises one or more CDR-H sequences, including one or more exemplary CDR-H sequences and variants thereof provided in this disclosure, consisting of one or more exemplary CDR-H sequences and variants thereof provided in this disclosure, or substantially consisting of one or more exemplary CDR-H sequences and variants thereof provided in this disclosure.

[0098] 2.2.1. V containing the exemplary Kabat CDR H sequence

[0099] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises one or more Kabat CDR-H sequences, including one or more exemplary Kabat CDR-H sequences and variants thereof provided in this disclosure, consisting of one or more exemplary Kabat CDR-H sequences and variants thereof provided in this disclosure, or consisting substantially of one or more exemplary Kabat CDR-H sequences and variants thereof provided in this disclosure.

[0100] 2.2.1.1. Kabat CDR-H3

[0101] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes sequences selected from SEQ ID NO:76-101, consists of sequences selected from SEQ ID NO:76-101, or consists substantially of sequences selected from SEQ ID NO:76-101. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:76, is composed of SEQ ID NO:76, or is substantially composed of SEQ ID NO:76. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:77, is composed of SEQ ID NO:77, or is substantially composed of SEQ ID NO:77. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:78, is composed of SEQ ID NO:78, or is substantially composed of SEQ ID NO:78. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:79, is composed of SEQ ID NO:79, or is substantially composed of SEQ ID NO:79. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:80, is composed of SEQ ID NO:80, or is substantially composed of SEQ ID NO:80. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:81, is composed of SEQ ID NO:81, or is substantially composed of SEQ ID NO:81. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:82, is composed of SEQ ID NO:82, or is substantially composed of SEQ ID NO:82. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:83, is composed of SEQ ID NO:83, or is substantially composed of SEQ ID NO:83. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:84, is composed of SEQ ID NO:84, or is substantially composed of SEQ ID NO:84. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:85, is composed of SEQ ID NO:85, or is substantially composed of SEQ ID NO:85. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:86, is composed of SEQ ID NO:86, or is substantially composed of SEQ ID NO:86. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:87, is composed of SEQ ID NO:87, or is substantially composed of SEQ ID NO:87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:88, is composed of SEQ ID NO:88, or is substantially composed of SEQ ID NO:88. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:89, is composed of SEQ ID NO:89, or is substantially composed of SEQ ID NO:89. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:90, is composed of SEQ ID NO:90, or is substantially composed of SEQ ID NO:90. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:91, is composed of SEQ ID NO:91, or is substantially composed of SEQ ID NO:91. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:92, is composed of SEQ ID NO:92, or is substantially composed of SEQ ID NO:92. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:94, is composed of SEQ ID NO:94, or is substantially composed of SEQ ID NO:94. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:95, is composed of SEQ ID NO:95, or is substantially composed of SEQ ID NO:95. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:96, is composed of SEQ ID NO:96, or is substantially composed of SEQ ID NO:96. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:97, is composed of SEQ ID NO:97, or is substantially composed of SEQ ID NO:97. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:98, is composed of SEQ ID NO:98, or is substantially composed of SEQ ID NO:98. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:99, is composed of SEQ ID NO:99, or is substantially composed of SEQ ID NO:99. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H3 sequence, which includes SEQ ID NO:100, is composed of SEQ ID NO:100, or is substantially composed of SEQ ID NO:100. In some aspects, the antibody comprises V H Sequence, the V H The sequence contains the Kabat CDR-H3 sequence, which includes SEQ ID NO:101, consists of SEQ ID NO:101, or is substantially composed of SEQ ID NO:101.

[0102] 2.2.1.2.Kabat CDR-H2

[0103] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes sequences selected from SEQ ID NO:54-71, consists of sequences selected from SEQ ID NO:54-71, or consists substantially of sequences selected from SEQ ID NO:54-71. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:54, is composed of SEQ ID NO:54, or is substantially composed of SEQ ID NO:54. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:55, is composed of SEQ ID NO:55, or is substantially composed of SEQ ID NO:55. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:56, is composed of SEQ ID NO:56, or is substantially composed of SEQ ID NO:56. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:57, is composed of SEQ ID NO:57, or is substantially composed of SEQ ID NO:57. In some aspects, the antibody comprises V HSequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:58, is composed of SEQ ID NO:58, or is substantially composed of SEQ ID NO:58. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:59, is composed of SEQ ID NO:59, or is substantially composed of SEQ ID NO:59. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:60, is composed of SEQ ID NO:60, or is substantially composed of SEQ ID NO:60. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:61, is composed of SEQ ID NO:61, or is substantially composed of SEQ ID NO:61. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:62, is composed of SEQ ID NO:62, or is substantially composed of SEQ ID NO:62. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:63, is composed of SEQ ID NO:63, or is substantially composed of SEQ ID NO:63. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:64, is composed of SEQ ID NO:64, or is substantially composed of SEQ ID NO:64. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:65, is composed of SEQ ID NO:65, or is substantially composed of SEQ ID NO:65. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:66, is composed of SEQ ID NO:66, or is substantially composed of SEQ ID NO:66. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:67, is composed of SEQ ID NO:67, or is substantially composed of SEQ ID NO:67. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:68, is composed of SEQ ID NO:68, or is substantially composed of SEQ ID NO:68. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:69, is composed of SEQ ID NO:69, or is substantially composed of SEQ ID NO:69. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H2 sequence, which includes SEQ ID NO:70, is composed of SEQ ID NO:70, or is substantially composed of SEQ ID NO:70. In some aspects, the antibody comprises V H Sequence, the V H The sequence contains the Kabat CDR-H2 sequence, which includes SEQ ID NO:71, consists of SEQ ID NO:71, or is substantially composed of SEQ ID NO:71.

[0104] 2.2.1.3. Kabat CDR-H1

[0105] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence, which includes sequences selected from SEQ ID NO:18-34, consists of sequences selected from SEQ ID NO:18-34, or consists substantially of sequences selected from SEQ ID NO:18-34. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:18, consists of SEQ ID NO:18, or is substantially composed of SEQ ID NO:18. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:19, is composed of SEQ ID NO:19, or is substantially composed of SEQ ID NO:19. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:20, consists of SEQ ID NO:20, or is substantially composed of SEQ ID NO:20. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:21, is composed of SEQ ID NO:21, or is substantially composed of SEQ ID NO:21. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:22, is composed of SEQ ID NO:22, or is substantially composed of SEQ ID NO:22. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:23, is composed of SEQ ID NO:23, or is substantially composed of SEQ ID NO:23. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:24, is composed of SEQ ID NO:24, or is substantially composed of SEQ ID NO:24. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:25, is composed of SEQ ID NO:25, or is substantially composed of SEQ ID NO:25. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:26, is composed of SEQ ID NO:26, or is substantially composed of SEQ ID NO:26. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:27, is composed of SEQ ID NO:27, or is substantially composed of SEQ ID NO:27. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:28, is composed of SEQ ID NO:28, or is substantially composed of SEQ ID NO:28. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:29, is composed of SEQ ID NO:29, or is substantially composed of SEQ ID NO:29. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:30, is composed of SEQ ID NO:30, or is substantially composed of SEQ ID NO:30. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:31, is composed of SEQ ID NO:31, or is substantially composed of SEQ ID NO:31. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:32, is composed of SEQ ID NO:32, or is substantially composed of SEQ ID NO:32. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence, which includes SEQ ID NO:33, and is composed of, or substantially composed of, SEQ ID NO:33. In some aspects, the antibody comprises V H Sequence, the V H The sequence contains the Kabat CDR-H1 sequence, which includes SEQ ID NO:34, consists of SEQ ID NO:34, or is substantially composed of SEQ ID NO:34.

[0106] 2.2.1.4.Kabat CDR-H3+Kabat CDR-H2

[0107] In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H3 sequence, which comprises sequences selected from SEQ ID NO:76-101, consists of sequences selected from SEQ ID NO:76-101, or consists substantially of sequences selected from SEQ ID NO:76-101; and the Kabat CDR-H2 sequence, which comprises sequences selected from SEQ ID NO:54-71, consists of sequences selected from SEQ ID NO:54-71, or consists substantially of sequences selected from SEQ ID NO:54-71. In some aspects, both the Kabat CDR-H3 and Kabat CDR-H2 sequences are derived from a single exemplary V provided in this disclosure. H Sequences. For example, in some respects, both Kabat CDR-H3 and Kabat CDR-H2 are derived from a single exemplary V selected from SEQ ID NO:170-200. H sequence.

[0108] 2.2.1.5.Kabat CDR-H3+Kabat CDR-H1

[0109] In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H3 sequence, which comprises sequences selected from SEQ ID NO:76-101, consisting of sequences selected from SEQ ID NO:76-101, or substantially consisting of sequences selected from SEQ ID NO:76-101; and the Kabat CDR-H1 sequence, which comprises sequences selected from SEQ ID NO:18-34, consisting of sequences selected from SEQ ID NO:18-34, or substantially consisting of sequences selected from SEQ ID NO:18-34. In some aspects, both the Kabat CDR-H3 and Kabat CDR-H1 sequences are derived from a single exemplary V provided in this disclosure. H Sequences. For example, in some respects, both Kabat CDR-H3 and Kabat CDR-H1 are derived from a single exemplary V selected from SEQ ID NO:170-200. H sequence.

[0110] 2.2.1.6.Kabat CDR-H1+Kabat CDR-H2

[0111] In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence, which comprises sequences selected from SEQ ID NO:18-34, consisting of sequences selected from SEQ ID NO:18-34, or substantially consisting of sequences selected from SEQ ID NO:18-34; and the Kabat CDR-H2 sequence, which comprises sequences selected from SEQ ID NO:54-71, consisting of sequences selected from SEQ ID NO:54-71, or substantially consisting of sequences selected from SEQ ID NO:54-71. In some aspects, both the Kabat CDR-H1 and Kabat CDR-H2 sequences are derived from a single exemplary V provided in this disclosure. H Sequences. For example, in some respects, both Kabat CDR-H1 and Kabat CDR-H2 are derived from a single exemplary V selected from SEQ ID NO:170-200. H sequence.

[0112] 2.2.1.7.Kabat CDR-H1+Kabat CDR-H2+Kabat CDR-H3

[0113] In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence, which comprises sequences selected from SEQ ID NO:18-34, consisting of sequences selected from SEQ ID NO:18-34, or substantially consisting of sequences selected from SEQ ID NO:18-34; the Kabat CDR-H2 sequence, which comprises sequences selected from SEQ ID NO:54-71, consisting of sequences selected from SEQ ID NO:54-71, or substantially consisting of sequences selected from SEQ ID NO:54-71; and the Kabat CDR-H3 sequence, which comprises sequences selected from SEQ ID NO:76-101, consisting of sequences selected from SEQ ID NO:76-101, or substantially consisting of sequences selected from SEQ ID NO:76-101. In some aspects, the Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 sequences are all derived from a single exemplary V provided in this disclosure. H Sequences. For example, in some respects, Kabat CDR-H1, Kabat CDR-H2, and Kabat CDR-H3 are all derived from a single exemplary V selected from SEQ ID NO:170-200. H sequence.

[0114] In some respects, the antibody contains V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:18, the Kabat CDR-H2 sequence comprising SEQ ID NO:54, and the Kabat CDR-H3 sequence comprising SEQ ID NO:76. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:19, the Kabat CDR-H2 sequence comprising SEQ ID NO:55, and the Kabat CDR-H3 sequence comprising SEQ ID NO:77. In some aspects, the antibody comprises V H Sequence, the V HThe sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:20, the Kabat CDR-H2 sequence comprising SEQ ID NO:56, and the Kabat CDR-H3 sequence comprising SEQ ID NO:78. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:21, the Kabat CDR-H2 sequence comprising SEQ ID NO:57, and the Kabat CDR-H3 sequence comprising SEQ ID NO:79. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:22, the Kabat CDR-H2 sequence comprising SEQ ID NO:58, and the Kabat CDR-H3 sequence comprising SEQ ID NO:80. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:21, the Kabat CDR-H2 sequence comprising SEQ ID NO:57, and the Kabat CDR-H3 sequence comprising SEQ ID NO:76. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:23, the Kabat CDR-H2 sequence comprising SEQ ID NO:59, and the Kabat CDR-H3 sequence comprising SEQ ID NO:76. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:23, the Kabat CDR-H2 sequence comprising SEQ ID NO:60, and the Kabat CDR-H3 sequence comprising SEQ ID NO:81. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:23, the Kabat CDR-H2 sequence comprising SEQ ID NO:59, and the Kabat CDR-H3 sequence comprising SEQ ID NO:82. In some aspects, the antibody comprises V H Sequence, the V HThe sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:23, the Kabat CDR-H2 sequence comprising SEQ ID NO:59, and the Kabat CDR-H3 sequence comprising SEQ ID NO:76. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:23, the Kabat CDR-H2 sequence comprising SEQ ID NO:59, and the Kabat CDR-H3 sequence comprising SEQ ID NO:81. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:21, the Kabat CDR-H2 sequence comprising SEQ ID NO:57, and the Kabat CDR-H3 sequence comprising SEQ ID NO:83. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:21, the Kabat CDR-H2 sequence comprising SEQ ID NO:57, and the Kabat CDR-H3 sequence comprising SEQ ID NO:84. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:24, the Kabat CDR-H2 sequence comprising SEQ ID NO:61, and the Kabat CDR-H3 sequence comprising SEQ ID NO:85. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:24, the Kabat CDR-H2 sequence comprising SEQ ID NO:61, and the Kabat CDR-H3 sequence comprising SEQ ID NO:86. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:25, the Kabat CDR-H2 sequence comprising SEQ ID NO:62, and the Kabat CDR-H3 sequence comprising SEQ ID NO:87. In some aspects, the antibody comprises V H Sequence, the V HThe sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:26, the Kabat CDR-H2 sequence comprising SEQ ID NO:63, and the Kabat CDR-H3 sequence comprising SEQ ID NO:88. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:26, the Kabat CDR-H2 sequence comprising SEQ ID NO:63, and the Kabat CDR-H3 sequence comprising SEQ ID NO:89. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:25, the Kabat CDR-H2 sequence comprising SEQ ID NO:63, and the Kabat CDR-H3 sequence comprising SEQ ID NO:90. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:27, the Kabat CDR-H2 sequence comprising SEQ ID NO:64, and the Kabat CDR-H3 sequence comprising SEQ ID NO:90. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:28, the Kabat CDR-H2 sequence comprising SEQ ID NO:62, and the Kabat CDR-H3 sequence comprising SEQ ID NO:91. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:29, the Kabat CDR-H2 sequence comprising SEQ ID NO:64, and the Kabat CDR-H3 sequence comprising SEQ ID NO:92. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:25, the Kabat CDR-H2 sequence comprising SEQ ID NO:65, and the Kabat CDR-H3 sequence comprising SEQ ID NO:93. In some aspects, the antibody comprises V H Sequence, the V HThe sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:30, the Kabat CDR-H2 sequence comprising SEQ ID NO:66, and the Kabat CDR-H3 sequence comprising SEQ ID NO:94. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:31, the Kabat CDR-H2 sequence comprising SEQ ID NO:67, and the Kabat CDR-H3 sequence comprising SEQ ID NO:95. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:32, the Kabat CDR-H2 sequence comprising SEQ ID NO:68, and the Kabat CDR-H3 sequence comprising SEQ ID NO:96. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:33, the Kabat CDR-H2 sequence comprising SEQ ID NO:69, and the Kabat CDR-H3 sequence comprising SEQ ID NO:97. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:34, the Kabat CDR-H2 sequence comprising SEQ ID NO:70, and the Kabat CDR-H3 sequence comprising SEQ ID NO:98. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:18, the Kabat CDR-H2 sequence comprising SEQ ID NO:54, and the Kabat CDR-H3 sequence comprising SEQ ID NO:99. In some aspects, the antibody comprises V H Sequence, the V H The sequences include the Kabat CDR-H1 sequence comprising SEQ ID NO:31, the Kabat CDR-H2 sequence comprising SEQ ID NO:71, and the Kabat CDR-H3 sequence comprising SEQ ID NO:100. In some aspects, the antibody comprises V H Sequence, the V HThe sequences include the Kabat CDR-H1 sequence including SEQ ID NO:24, the Kabat CDR-H2 sequence including SEQ ID NO:61, and the Kabat CDR-H3 sequence including SEQ ID NO:101.

[0115] 2.2.1.8. V containing the exemplary Kabat CDR H Sequence variants

[0116] In some implementations, the V provided herein H The sequences include variants of the exemplary KabatCDR-H3, CDR-H2 and / or CDR-H1 sequences provided in this disclosure.

[0117] In some aspects, the Kabat CDR-H3 sequence includes variants of the exemplary Kabat CDR-H3 sequence provided in this disclosure, consists of variants of the exemplary Kabat CDR-H3 sequence provided in this disclosure, or consists substantially of variants of the exemplary Kabat CDR-H3 sequence provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence includes sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Kabat CDR-H3 sequence provided in this disclosure, consists of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Kabat CDR-H3 sequence provided in this disclosure, or consists substantially of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Kabat CDR-H3 sequence provided in this disclosure. In some aspects, the Kabat CDR-H3 sequence comprises any exemplary Kabat CDR-H3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary Kabat CDR-H3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0118] In some aspects, the Kabat CDR-H2 sequence includes variants of the exemplary Kabat CDR-H2 sequence provided in this disclosure, consists of variants of the exemplary Kabat CDR-H2 sequence provided in this disclosure, or consists substantially of variants of the exemplary Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence includes sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Kabat CDR-H2 sequence provided in this disclosure, consists of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Kabat CDR-H2 sequence provided in this disclosure, or consists substantially of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Kabat CDR-H2 sequence provided in this disclosure. In some aspects, the Kabat CDR-H2 sequence includes any exemplary Kabat CDR-H2 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary Kabat CDR-H2 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0119] In some aspects, the Kabat CDR-H1 sequence includes variants of the exemplary Kabat CDR-H1 sequence provided in this disclosure, consists of variants of the exemplary Kabat CDR-H1 sequence provided in this disclosure, or consists substantially of variants of the exemplary Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence includes sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Kabat CDR-H1 sequence provided in this disclosure, consists of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Kabat CDR-H1 sequence provided in this disclosure, or consists substantially of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Kabat CDR-H1 sequence provided in this disclosure. In some aspects, the Kabat CDR-H1 sequence comprises any exemplary Kabat CDR-H1 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, consists of any exemplary Kabat CDR-H1 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary Kabat CDR-H1 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0120] 2.2.2. V containing the exemplary Chothia CDR H sequence

[0121] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises one or more Chothia CDR-H sequences, including one or more exemplary Chothia CDR-H sequences and variants thereof provided in this disclosure, consisting of one or more exemplary Chothia CDR-H sequences and variants thereof provided in this disclosure, or substantially consisting of one or more exemplary Chothia CDR-H sequences and variants thereof provided in this disclosure.

[0122] 2.2.2.1.Chothia CDR-H3

[0123] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H3 sequence, which includes sequences selected from SEQ ID NO:76-101, consists of sequences selected from SEQ ID NO:76-101, or consists substantially of sequences selected from SEQ ID NO:76-101. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:76, is composed of SEQ ID NO:76, or is substantially composed of SEQ ID NO:76. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:77, is composed of SEQ ID NO:77, or is substantially composed of SEQ ID NO:77. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:78, is composed of SEQ ID NO:78, or is substantially composed of SEQ ID NO:78. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:79, is composed of SEQ ID NO:79, or is substantially composed of SEQ ID NO:79. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the ChothiaCDR-H3 sequence, which includes SEQ ID NO:80, is composed of SEQ ID NO:80, or is substantially composed of SEQ ID NO:80. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:81, is composed of SEQ ID NO:81, or is substantially composed of SEQ ID NO:81. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:82, is composed of SEQ ID NO:82, or is substantially composed of SEQ ID NO:82. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:83, is composed of SEQ ID NO:83, or is substantially composed of SEQ ID NO:83. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:84, is composed of SEQ ID NO:84, or is substantially composed of SEQ ID NO:84. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:85, is composed of SEQ ID NO:85, or is substantially composed of SEQ ID NO:85. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:86, is composed of SEQ ID NO:86, or is substantially composed of SEQ ID NO:86. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:87, is composed of SEQ ID NO:87, or is substantially composed of SEQ ID NO:87. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:88, is composed of SEQ ID NO:88, or is substantially composed of SEQ ID NO:88. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:89, is composed of SEQ ID NO:89, or is substantially composed of SEQ ID NO:89. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:90, is composed of SEQ ID NO:90, or is substantially composed of SEQ ID NO:90. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:91, is composed of SEQ ID NO:91, or is substantially composed of SEQ ID NO:91. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:92, is composed of SEQ ID NO:92, or is substantially composed of SEQ ID NO:92. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:93, is composed of SEQ ID NO:93, or is substantially composed of SEQ ID NO:93. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:94, is composed of SEQ ID NO:94, or is substantially composed of SEQ ID NO:94. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:95, is composed of SEQ ID NO:95, or is substantially composed of SEQ ID NO:95. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:96, is composed of SEQ ID NO:96, or is substantially composed of SEQ ID NO:96. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:97, is composed of SEQ ID NO:97, or is substantially composed of SEQ ID NO:97. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:98, is composed of SEQ ID NO:98, or is substantially composed of SEQ ID NO:98. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:99, is composed of SEQ ID NO:99, or is substantially composed of SEQ ID NO:99. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H3 sequence, which includes SEQ ID NO:100, is composed of SEQ ID NO:100, or is substantially composed of SEQ ID NO:100. In some aspects, the antibody comprises V H Sequence, the V H The sequence contains the Chothia CDR-H3 sequence, which includes SEQ ID NO:101, is composed of SEQ ID NO:101, or is substantially composed of SEQ ID NO:101.

[0124] 2.2.2.2.Chothia CDR-H2

[0125] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises a Chothia CDR-H2 sequence, which includes sequences selected from SEQ ID NO:38-50, consists of sequences selected from SEQ ID NO:38-50, or consists substantially of sequences selected from SEQ ID NO:38-50. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:38, is composed of SEQ ID NO:38, or is substantially composed of SEQ ID NO:38. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:39, is composed of SEQ ID NO:39, or is substantially composed of SEQ ID NO:39. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:40, is composed of SEQ ID NO:40, or is substantially composed of SEQ ID NO:40. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the ChothiaCDR-H2 sequence, which includes SEQ ID NO:41, is composed of SEQ ID NO:41, or is substantially composed of SEQ ID NO:41. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:42, is composed of SEQ ID NO:42, or is substantially composed of SEQ ID NO:42. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:43, is composed of SEQ ID NO:43, or is substantially composed of SEQ ID NO:43. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:44, is composed of SEQ ID NO:44, or is substantially composed of SEQ ID NO:44. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:45, is composed of SEQ ID NO:45, or is substantially composed of SEQ ID NO:45. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:46, is composed of SEQ ID NO:46, or is substantially composed of SEQ ID NO:46. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:47, is composed of SEQ ID NO:47, or is substantially composed of SEQ ID NO:47. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:48, is composed of SEQ ID NO:48, or is substantially composed of SEQ ID NO:48. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H2 sequence, which includes SEQ ID NO:49, is composed of SEQ ID NO:49, or is substantially composed of SEQ ID NO:49. In some aspects, the antibody comprises V H Sequence, the V H The sequence contains the Chothia CDR-H2 sequence, which includes SEQ ID NO:50, consists of SEQ ID NO:50, or is substantially composed of SEQ ID NO:50.

[0126] 2.2.2.3.Chothia CDR-H1

[0127] In some embodiments, the antibody comprises V HSequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes sequences selected from SEQ ID NO:1-14, consists of sequences selected from SEQ ID NO:1-14, or consists substantially of sequences selected from SEQ ID NO:1-14. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:1, is composed of SEQ ID NO:1, or is substantially composed of SEQ ID NO:1. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:2, is composed of SEQ ID NO:2, or is substantially composed of SEQ ID NO:2. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the ChothiaCDR-H1 sequence, which includes SEQ ID NO:3, is composed of SEQ ID NO:3, or is substantially composed of SEQ ID NO:3. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:4, is composed of SEQ ID NO:4, or is substantially composed of SEQ ID NO:4. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:5, is composed of SEQ ID NO:5, or is substantially composed of SEQ ID NO:5. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:6, is composed of SEQ ID NO:6, or is substantially composed of SEQ ID NO:6. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:7, is composed of SEQ ID NO:7, or is substantially composed of SEQ ID NO:7. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:8, and is composed of, or substantially composed of, SEQ ID NO:8. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:9, is composed of SEQ ID NO:9, or is substantially composed of SEQ ID NO:9. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:10, is composed of SEQ ID NO:10, or is substantially composed of SEQ ID NO:10. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:11, is composed of SEQ ID NO:11, or is substantially composed of SEQ ID NO:11. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence, which includes SEQ ID NO:12, is composed of SEQ ID NO:12, or is substantially composed of SEQ ID NO:12. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the ChothiaCDR-H1 sequence, which includes SEQ ID NO:13, is composed of SEQ ID NO:13, or is substantially composed of SEQ ID NO:13. In some aspects, the antibody comprises V H Sequence, the V HThe sequence contains the Chothia CDR-H1 sequence, which includes SEQ ID NO:14, consists of SEQ ID NO:14, or is substantially composed of SEQ ID NO:14.

[0128] 2.2.2.4.Chothia CDR-H3+Chothia CDR-H2

[0129] In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H3 sequence, which comprises sequences selected from SEQ ID NO:76-101, consisting of sequences selected from SEQ ID NO:76-101, or substantially consisting of sequences selected from SEQ ID NO:76-101; and the Chothia CDR-H2 sequence, which comprises sequences selected from SEQ ID NO:38-50, consisting of sequences selected from SEQ ID NO:38-50, or substantially consisting of sequences selected from SEQ ID NO:38-50. In some aspects, both the Chothia CDR-H3 and Chothia CDR-H2 sequences are derived from a single exemplary V provided in this disclosure. H Sequences. For example, in some respects, both Chothia CDR-H3 and Chothia CDR-H2 are derived from a single exemplary V selected from SEQ ID NO:170-200. H sequence.

[0130] 2.2.2.5.Chothia CDR-H3+Chothia CDR-H1

[0131] In some embodiments, the antibody comprises V H Sequence, the V HThe sequence comprises a Chothia CDR-H3 sequence, which includes sequences selected from SEQ ID NO:76-101, consisting of sequences selected from SEQ ID NO:76-101, or substantially consisting of sequences selected from SEQ ID NO:76-101; and a Chothia CDR-H1 sequence, which includes sequences selected from SEQ ID NO:1-14, consisting of sequences selected from SEQ ID NO:1-14, or substantially consisting of sequences selected from SEQ ID NO:1-14. In some aspects, both the Chothia CDR-H3 and Chothia CDR-H1 sequences are derived from a single exemplary V provided in this disclosure. H Sequences. For example, in some respects, both Chothia CDR-H3 and Chothia CDR-H1 are derived from a single exemplary V selected from SEQ ID NO:170-200. H sequence.

[0132] 2.2.2.6.Chothia CDR-H1+Chothia CDR-H2

[0133] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises a Chothia CDR-H1 sequence, which includes sequences selected from SEQ ID NO:1-14, consists of sequences selected from SEQ ID NO:1-14, or consists substantially of sequences selected from SEQ ID NO:1-14; and a Chothia CDR-H2 sequence, which includes sequences selected from SEQ ID NO:38-50, consists of sequences selected from SEQ ID NO:38-50, or consists substantially of sequences selected from SEQ ID NO:38-50. In some aspects, both the Chothia CDR-H1 and Chothia CDR-H2 sequences are derived from a single exemplary V provided in this disclosure. H Sequences. For example, in some respects, both Chothia CDR-H1 and Chothia CDR-H2 are derived from a single exemplary V selected from SEQ ID NO:170-200. H sequence.

[0134] 2.2.2.7.Chothia CDR-H1+Chothia CDR-H2+Chothia CDR-H3

[0135] In some embodiments, the antibody comprises V H Sequence, the V H The sequence comprises: a Chothia CDR-H1 sequence, which includes sequences selected from SEQ ID NO:1-14, consisting of sequences selected from SEQ ID NO:1-14, or consisting substantially of sequences selected from SEQ ID NO:1-14; a Chothia CDR-H2 sequence, which includes sequences selected from SEQ ID NO:38-50, consisting of sequences selected from SEQ ID NO:38-50, or consisting substantially of sequences selected from SEQ ID NO:38-50; and a Chothia CDR-H3 sequence, which includes sequences selected from SEQ ID NO:76-101, consisting of sequences selected from SEQ ID NO:76-101, or consisting substantially of sequences selected from SEQ ID NO:76-101. In some respects, the Chothia CDR-H1 sequence, the Chothia CDR-H2 sequence, and the Chothia CDR-H3 sequence all originate from a single exemplary V provided in this disclosure. H Sequences. For example, in some respects, Chothia CDR-H1, Chothia CDR-H2, and Chothia CDR-H3 are all derived from a single exemplary V selected from SEQ ID NO:170-200. H sequence.

[0136] In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence comprising SEQ ID NO:1, the Chothia CDR-H2 sequence comprising SEQ ID NO:38, and the Chothia CDR-H3 sequence comprising SEQ ID NO:76. In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence comprising SEQ ID NO:2, the Chothia CDR-H2 sequence comprising SEQ ID NO:39, and the Chothia CDR-H3 sequence comprising SEQ ID NO:77. In some embodiments, the antibody comprises V H Sequence, the V HThe sequences include the Chothia CDR-H1 sequence comprising SEQ ID NO:2, the Chothia CDR-H2 sequence comprising SEQ ID NO:40, and the Chothia CDR-H3 sequence comprising SEQ ID NO:78. In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO:3), the Chothia CDR-H2 sequence (SEQ ID NO:41), and the Chothia CDR-H3 sequence (SEQ ID NO:79). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence of SEQ ID NO:4, the Chothia CDR-H2 sequence of SEQ ID NO:41, and the Chothia CDR-H3 sequence of SEQ ID NO:80. In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO:3), the Chothia CDR-H2 sequence (SEQ ID NO:41), and the Chothia CDR-H3 sequence (SEQ ID NO:76). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence comprising SEQ ID NO:2, the Chothia CDR-H2 sequence comprising SEQ ID NO:42, and the Chothia CDR-H3 sequence comprising SEQ ID NO:76. In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence comprising SEQ ID NO:2, the Chothia CDR-H2 sequence comprising SEQ ID NO:43, and the Chothia CDR-H3 sequence comprising SEQ ID NO:81. In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence comprising SEQ ID NO:2, the Chothia CDR-H2 sequence comprising SEQ ID NO:42, and the Chothia CDR-H3 sequence comprising SEQ ID NO:82. In some embodiments, the antibody comprises VH Sequence, the V H The sequences include the ChothiaCDR-H1 sequence (SEQ ID NO: 5), the ChothiaCDR-H2 sequence (SEQ ID NO: 42), and the ChothiaCDR-H3 sequence (SEQ ID NO: 76). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence comprising SEQ ID NO:2, the Chothia CDR-H2 sequence comprising SEQ ID NO:42, and the Chothia CDR-H3 sequence comprising SEQ ID NO:81. In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence comprising SEQ ID NO:3, the Chothia CDR-H2 sequence comprising SEQ ID NO:41, and the Chothia CDR-H3 sequence comprising SEQ ID NO:83. In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO:3), the Chothia CDR-H2 sequence (SEQ ID NO:41), and the Chothia CDR-H3 sequence (SEQ ID NO:84). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO: 6), the Chothia CDR-H2 sequence (SEQ ID NO: 44), and the Chothia CDR-H3 sequence (SEQ ID NO: 85). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO: 6), the Chothia CDR-H2 sequence (SEQ ID NO: 44), and the Chothia CDR-H3 sequence (SEQ ID NO: 86). In some embodiments, the antibody comprises V H Sequence, the V HThe sequences include the Chothia CDR-H1 sequence (SEQ ID NO:7), the Chothia CDR-H2 sequence (SEQ ID NO:45), and the Chothia CDR-H3 sequence (SEQ ID NO:87). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO: 8), the Chothia CDR-H2 sequence (SEQ ID NO: 44), and the Chothia CDR-H3 sequence (SEQ ID NO: 88). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO: 8), the Chothia CDR-H2 sequence (SEQ ID NO: 44), and the Chothia CDR-H3 sequence (SEQ ID NO: 89). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO:7), the Chothia CDR-H2 sequence (SEQ ID NO:44), and the Chothia CDR-H3 sequence (SEQ ID NO:90). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the ChothiaCDR-H1 sequence (SEQ ID NO: 9), the ChothiaCDR-H2 sequence (SEQ ID NO: 44), and the ChothiaCDR-H3 sequence (SEQ ID NO: 90). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence of SEQ ID NO:6, the Chothia CDR-H2 sequence of SEQ ID NO:45, and the Chothia CDR-H3 sequence of SEQ ID NO:91. In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO: 8), the Chothia CDR-H2 sequence (SEQ ID NO: 44), and the Chothia CDR-H3 sequence (SEQ ID NO: 92). In some embodiments, the antibody comprises VH Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO:7), the Chothia CDR-H2 sequence (SEQ ID NO:44), and the Chothia CDR-H3 sequence (SEQ ID NO:93). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO: 10), the Chothia CDR-H2 sequence (SEQ ID NO: 46), and the Chothia CDR-H3 sequence (SEQ ID NO: 94). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO: 11), the Chothia CDR-H2 sequence (SEQ ID NO: 47), and the Chothia CDR-H3 sequence (SEQ ID NO: 95). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO:12), the Chothia CDR-H2 sequence (SEQ ID NO:48), and the Chothia CDR-H3 sequence (SEQ ID NO:96). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence (SEQ ID NO: 13), the Chothia CDR-H2 sequence (SEQ ID NO: 44), and the Chothia CDR-H3 sequence (SEQ ID NO: 97). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence of SEQ ID NO:14, the Chothia CDR-H2 sequence of SEQ ID NO:49, and the Chothia CDR-H3 sequence of SEQ ID NO:98. In some embodiments, the antibody comprises V H Sequence, the V HThe sequences include the Chothia CDR-H1 sequence comprising SEQ ID NO:1, the Chothia CDR-H2 sequence comprising SEQ ID NO:38, and the Chothia CDR-H3 sequence comprising SEQ ID NO:99. In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the ChothiaCDR-H1 sequence (SEQ ID NO:11), the ChothiaCDR-H2 sequence (SEQ ID NO:50), and the ChothiaCDR-H3 sequence (SEQ ID NO:100). In some embodiments, the antibody comprises V H Sequence, the V H The sequences include the Chothia CDR-H1 sequence including SEQ ID NO:6, the Chothia CDR-H2 sequence including SEQ ID NO:44, and the Chothia CDR-H3 sequence including SEQ ID NO:101.

[0137] 2.2.2.8. V containing the exemplary Chothia CDR H Sequence variants

[0138] In some implementations, the V provided herein H The sequences include variants of the exemplary ChothiaCDR-H3, CDR-H2 and / or CDR-H1 sequences provided in this disclosure.

[0139] In some aspects, the Chothia CDR-H3 sequence includes variants of the exemplary Chothia CDR-H3 sequence provided in this disclosure, consists of variants of the exemplary Chothia CDR-H3 sequence provided in this disclosure, or consists substantially of variants of the exemplary Chothia CDR-H3 sequence provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence includes sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Chothia CDR-H3 sequence provided in this disclosure, consists of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Chothia CDR-H3 sequence provided in this disclosure, or consists substantially of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Chothia CDR-H3 sequence provided in this disclosure. In some aspects, the Chothia CDR-H3 sequence includes any exemplary Chothia CDR-H3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary Chothia CDR-H3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0140] In some aspects, the Chothia CDR-H2 sequence includes variants of the exemplary Chothia CDR-H2 sequence provided in this disclosure, consists of variants of the exemplary Chothia CDR-H2 sequence provided in this disclosure, or consists substantially of variants of the exemplary Chothia CDR-H2 sequence provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence includes sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Chothia CDR-H2 sequence provided in this disclosure, consists of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Chothia CDR-H2 sequence provided in this disclosure, or consists substantially of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Chothia CDR-H2 sequence provided in this disclosure. In some aspects, the Chothia CDR-H2 sequence includes any exemplary Chothia CDR-H2 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary Chothia CDR-H2 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0141] In some aspects, the Chothia CDR-H1 sequence includes variants of the exemplary Chothia CDR-H1 sequence provided in this disclosure, consists of variants of the exemplary Chothia CDR-H1 sequence provided in this disclosure, or consists substantially of variants of the exemplary Chothia CDR-H1 sequence provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence includes sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Chothia CDR-H1 sequence provided in this disclosure, consists of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Chothia CDR-H1 sequence provided in this disclosure, or consists substantially of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary Chothia CDR-H1 sequence provided in this disclosure. In some aspects, the Chothia CDR-H1 sequence includes any exemplary Chothia CDR-H1 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary Chothia CDR-H1 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0142] 2.3.V H sequence

[0143] In some embodiments, the antibody comprises V H Sequence, the V H The sequence includes sequences selected from SEQ ID NO:170-200, consists of sequences selected from SEQ ID NO:170-200, or consists substantially of sequences selected from SEQ ID NO:170-200. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:170, consists of SEQ ID NO:170, or is substantially composed of SEQ ID NO:170. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:171, consists of SEQ ID NO:171, or is substantially composed of SEQ ID NO:171. In some aspects, the antibody comprises V H Sequence, the V HThe sequence includes SEQ ID NO:172, consists of SEQ ID NO:172, or is substantially composed of SEQ ID NO:172. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:173, consists of SEQ ID NO:173, or is substantially composed of SEQ ID NO:173. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:174, consists of SEQ ID NO:174, or is substantially composed of SEQ ID NO:174. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:175, consists of SEQ ID NO:175, or is substantially composed of SEQ ID NO:175. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:176, consists of SEQ ID NO:176, or is substantially composed of SEQ ID NO:176. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:177, consists of SEQ ID NO:177, or is substantially composed of SEQ ID NO:177. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:178, consists of SEQ ID NO:178, or is substantially composed of SEQ ID NO:178. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:179, consists of SEQ ID NO:179, or is substantially composed of SEQ ID NO:179. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:180, consists of SEQ ID NO:180, or is substantially composed of SEQ ID NO:180. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:181, consists of SEQ ID NO:181, or is substantially composed of SEQ ID NO:181. In some aspects, the antibody comprises V H Sequence, the VH The sequence includes SEQ ID NO:182, consists of SEQ ID NO:182, or is substantially composed of SEQ ID NO:182. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:183, consists of SEQ ID NO:183, or is substantially composed of SEQ ID NO:183. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:184, consists of SEQ ID NO:184, or is substantially composed of SEQ ID NO:184. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:185, consists of SEQ ID NO:185, or is substantially composed of SEQ ID NO:185. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:186, consists of SEQ ID NO:186, or is substantially composed of SEQ ID NO:186. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:187, consists of SEQ ID NO:187, or is substantially composed of SEQ ID NO:187. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:188, consists of SEQ ID NO:188, or is substantially composed of SEQ ID NO:188. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:189, consists of SEQ ID NO:189, or is substantially composed of SEQ ID NO:189. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:190, consists of SEQ ID NO:190, or is substantially composed of SEQ ID NO:190. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:191, consists of SEQ ID NO:191, or is substantially composed of SEQ ID NO:191. In some aspects, the antibody comprises V HSequence, the V H The sequence includes SEQ ID NO:192, consists of SEQ ID NO:192, or is substantially composed of SEQ ID NO:192. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:193, consists of SEQ ID NO:193, or is substantially composed of SEQ ID NO:193. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:194, consists of SEQ ID NO:194, or is substantially composed of SEQ ID NO:194. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:195, consists of SEQ ID NO:195, or is substantially composed of SEQ ID NO:195. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:196, consists of SEQ ID NO:196, or is substantially composed of SEQ ID NO:196. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:197, consists of SEQ ID NO:197, or is substantially composed of SEQ ID NO:197. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:198, consists of SEQ ID NO:198, or is substantially composed of SEQ ID NO:198. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:199, consists of SEQ ID NO:199, or is substantially composed of SEQ ID NO:199. In some aspects, the antibody comprises V H Sequence, the V H The sequence includes SEQ ID NO:200, consists of SEQ ID NO:200, or consists essentially of SEQ ID NO:200.

[0144] 2.3.1.V H Sequence variants

[0145] In some implementations, the V provided herein H The sequence includes the exemplary V provided in this disclosure.H Variations of the sequence, as exemplified by V provided in this disclosure H The sequence consists of variants, or is substantially composed of the exemplary V provided in this disclosure. H Composition of sequence variants.

[0146] In some respects, V H The sequence includes the exemplary V provided in this disclosure. H Variations of the sequence, as exemplified by V provided in this disclosure H The sequence consists of variants, or is substantially composed of the exemplary V provided in this disclosure. H The sequence consists of variants. In some respects, V H The sequence includes any exemplary V provided in this disclosure. H A sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity with any of the exemplary sequences provided in this disclosure. H The sequences consist of sequences having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity, or are substantially composed of sequences identical to any of the exemplary V sequences provided in this disclosure. H The sequence consists of sequences with at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identity.

[0147] In some implementation schemes, V H The sequence includes any exemplary V provided in this disclosure. H Sequence, as provided in this disclosure by any exemplary V H The sequence consists of, or is substantially composed of, any exemplary V provided in this disclosure. H Sequence composition, the exemplary V H The sequence has 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some respects, the amino acid substitutions are conserved.

[0148] 2.4. CDR-L3 sequence

[0149] In some embodiments, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising sequences selected from SEQ ID NO:149-166, consisting of sequences selected from SEQ ID NO:149-166, or substantially consisting of sequences selected from SEQ ID NO:149-166. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:149, consisting of SEQ ID NO:149, or substantially consisting of SEQ ID NO:149. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:150, consisting of SEQ ID NO:150, or substantially consisting of SEQ ID NO:150. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:151, consisting of SEQ ID NO:151, or substantially consisting of SEQ ID NO:151. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:152, consisting of, or substantially consisting of SEQ ID NO:152. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:153, consisting of, or substantially consisting of SEQ ID NO:153. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:154, consisting of, or substantially consisting of SEQ ID NO:154. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:155, consisting of, or substantially consisting of SEQ ID NO:155. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:156, or consisting essentially of SEQ ID NO:156. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:157, or consisting essentially of SEQ ID NO:157. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:158, or consisting essentially of SEQ ID NO:158.In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:159, consisting of, or substantially consisting of SEQ ID NO:159. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:160, consisting of, or substantially consisting of SEQ ID NO:160. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:161, consisting of, or substantially consisting of SEQ ID NO:161. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:162, consisting of, or substantially consisting of SEQ ID NO:162. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:163, consisting of, or substantially consisting of SEQ ID NO:163. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:164, consisting of, or substantially consisting of SEQ ID NO:164. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:165, consisting of, or substantially consisting of SEQ ID NO:165. In some aspects, the antibody comprises a CDR-L3 sequence, the CDR-L3 sequence comprising SEQ ID NO:166, consisting of, or substantially consisting of SEQ ID NO:166.

[0150] In some aspects, a CDR-L3 sequence includes variations of the exemplary CDR-L3 sequences provided in this disclosure, consists of variations of the exemplary CDR-L3 sequences provided in this disclosure, or is substantially composed of variations of the exemplary CDR-L3 sequences provided in this disclosure. In some aspects, a CDR-L3 sequence includes a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L3 sequence provided in this disclosure, consists of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L3 sequence provided in this disclosure, or is substantially composed of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises any exemplary CDR-L3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, consists of any exemplary CDR-L3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary CDR-L3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0151] 2.5. V containing exemplary CDRs L sequence

[0152] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises one or more CDR-L sequences, including one or more exemplary CDR-L sequences and variants thereof provided in this disclosure, consisting of one or more exemplary CDR-L sequences and variants thereof provided in this disclosure, or substantially consisting of one or more exemplary CDR-L sequences and variants thereof provided in this disclosure.

[0153] 2.5.1.CDR-L3

[0154] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, said CDR-L3 sequence comprising sequences selected from SEQ ID NO:149-166, consisting of sequences selected from SEQ ID NO:149-166, or substantially consisting of sequences selected from SEQ ID NO:149-166. In some aspects, the antibody comprises V L Sequence, the V LThe sequence includes a CDR-L3 sequence, which comprises SEQ ID NO:149, is composed of SEQ ID NO:149, or is substantially composed of SEQ ID NO:149. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:150, is composed of SEQ ID NO:150, or is substantially composed of SEQ ID NO:150. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:151, is composed of SEQ ID NO:151, or is substantially composed of SEQ ID NO:151. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:152, is composed of SEQ ID NO:152, or is substantially composed of SEQ ID NO:152. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:153, is composed of SEQ ID NO:153, or is substantially composed of SEQ ID NO:153. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:154, is composed of SEQ ID NO:154, or is substantially composed of SEQ ID NO:154. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:155, is composed of SEQ ID NO:155, or is substantially composed of SEQ ID NO:155. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:156, is composed of SEQ ID NO:156, or is substantially composed of SEQ ID NO:156. In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:157, is composed of SEQ ID NO:157, or is substantially composed of SEQ ID NO:157. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes a CDR-L3 sequence, which comprises SEQ ID NO:158, is composed of SEQ ID NO:158, or is substantially composed of SEQ ID NO:158. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:159, is composed of SEQ ID NO:159, or is substantially composed of SEQ ID NO:159. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:160, is composed of SEQ ID NO:160, or is substantially composed of SEQ ID NO:160. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:161, is composed of SEQ ID NO:161, or is substantially composed of SEQ ID NO:161. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:162, is composed of SEQ ID NO:162, or is substantially composed of SEQ ID NO:162. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:163, is composed of SEQ ID NO:163, or is substantially composed of SEQ ID NO:163. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:164, is composed of SEQ ID NO:164, or is substantially composed of SEQ ID NO:164. In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises a CDR-L3 sequence, which includes SEQ ID NO:165, is composed of SEQ ID NO:165, or is substantially composed of SEQ ID NO:165. In some aspects, the antibody comprises V L Sequence, the V L The sequence contains a CDR-L3 sequence, which includes SEQ ID NO:166, is composed of SEQ ID NO:166, or is substantially composed of SEQ ID NO:166.

[0155] 2.5.2.CDR-L2

[0156] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, said CDR-L2 sequence comprising sequences selected from SEQ ID NO:128-145, consisting of sequences selected from SEQ ID NO:128-145, or substantially consisting of sequences selected from SEQ ID NO:128-145. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:128, is composed of SEQ ID NO:128, or is substantially composed of SEQ ID NO:128. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:129, is composed of SEQ ID NO:129, or is substantially composed of SEQ ID NO:129. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:130, is composed of SEQ ID NO:130, or is substantially composed of SEQ ID NO:130. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:131, is composed of SEQ ID NO:131, or is substantially composed of SEQ ID NO:131. In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:132, is composed of SEQ ID NO:132, or is substantially composed of SEQ ID NO:132. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:133, is composed of SEQ ID NO:133, or is substantially composed of SEQ ID NO:133. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:134, is composed of SEQ ID NO:134, or is substantially composed of SEQ ID NO:134. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:135, is composed of SEQ ID NO:135, or is substantially composed of SEQ ID NO:135. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:136, is composed of SEQ ID NO:136, or is substantially composed of SEQ ID NO:136. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:137, is composed of SEQ ID NO:137, or is substantially composed of SEQ ID NO:137. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:138, is composed of SEQ ID NO:138, or is substantially composed of SEQ ID NO:138. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:139, is composed of SEQ ID NO:139, or is substantially composed of SEQ ID NO:139. In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:140, is composed of SEQ ID NO:140, or is substantially composed of SEQ ID NO:140. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:141, is composed of SEQ ID NO:141, or is substantially composed of SEQ ID NO:141. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:142, is composed of SEQ ID NO:142, or is substantially composed of SEQ ID NO:142. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:143, is composed of SEQ ID NO:143, or is substantially composed of SEQ ID NO:143. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L2 sequence, which includes SEQ ID NO:144, is composed of SEQ ID NO:144, or is substantially composed of SEQ ID NO:144. In some aspects, the antibody comprises V L Sequence, the V L The sequence contains a CDR-L2 sequence, which includes SEQ ID NO:145, is composed of SEQ ID NO:145, or is substantially composed of SEQ ID NO:145.

[0157] 2.5.3.CDR-L1

[0158] In some embodiments, the antibody comprises V L Sequence, the V L The sequence includes a CDR-L1 sequence, which comprises sequences selected from SEQ ID NO:105-124, consists of sequences selected from SEQ ID NO:105-124, or consists substantially of sequences selected from SEQ ID NO:105-124. In some aspects, the antibody comprises V L Sequence, the V LThe sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:105, is composed of SEQ ID NO:105, or is substantially composed of SEQ ID NO:105. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:106, is composed of SEQ ID NO:106, or is substantially composed of SEQ ID NO:106. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:107, and is composed of, or substantially composed of, SEQ ID NO:107. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes a CDR-L1 sequence, which comprises SEQ ID NO:108, is composed of SEQ ID NO:108, or is substantially composed of SEQ ID NO:108. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes a CDR-L1 sequence, which comprises SEQ ID NO:109, is composed of SEQ ID NO:109, or is substantially composed of SEQ ID NO:109. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:110, is composed of SEQ ID NO:110, or is substantially composed of SEQ ID NO:110. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes a CDR-L1 sequence, which comprises SEQ ID NO:111, is composed of SEQ ID NO:111, or is substantially composed of SEQ ID NO:111. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:112, and is composed of, or substantially composed of, SEQ ID NO:112. In some aspects, the antibody comprises V L Sequence, the V LThe sequence includes a CDR-L1 sequence, which comprises SEQ ID NO:113, is composed of SEQ ID NO:113, or is substantially composed of SEQ ID NO:113. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:114, is composed of SEQ ID NO:114, or is substantially composed of SEQ ID NO:114. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:115, is composed of SEQ ID NO:115, or is substantially composed of SEQ ID NO:115. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:116, and is composed of, or substantially composed of, SEQ ID NO:116. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:117, is composed of SEQ ID NO:117, or is substantially composed of SEQ ID NO:117. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:118, is composed of SEQ ID NO:118, or is substantially composed of SEQ ID NO:118. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes a CDR-L1 sequence, which comprises SEQ ID NO:119, is composed of SEQ ID NO:119, or is substantially composed of SEQ ID NO:119. In some aspects, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes SEQ ID NO:120, is composed of SEQ ID NO:120, or is substantially composed of SEQ ID NO:120. In some aspects, the antibody comprises V L Sequence, the V LThe sequence includes a CDR-L1 sequence, which comprises SEQ ID NO:121, is composed of SEQ ID NO:121, or is substantially composed of SEQ ID NO:121. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes a CDR-L1 sequence, which comprises SEQ ID NO:122, is composed of SEQ ID NO:122, or is substantially composed of SEQ ID NO:122. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes a CDR-L1 sequence, which comprises SEQ ID NO:123, is composed of SEQ ID NO:123, or is substantially composed of SEQ ID NO:123. In some aspects, the antibody comprises V L Sequence, the V L The sequence contains a CDR-L1 sequence, which includes SEQ ID NO:124, is composed of SEQ ID NO:124, or is substantially composed of SEQ ID NO:124.

[0159] 2.5.4.CDR-L3+CDR-L2

[0160] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L3 sequence, which includes sequences selected from SEQ ID NO:149-166, consisting of sequences selected from SEQ ID NO:149-166, or substantially consisting of sequences selected from SEQ ID NO:149-166; and a CDR-L2 sequence, which includes sequences selected from SEQ ID NO:128-145, consisting of sequences selected from SEQ ID NO:128-145, or substantially consisting of sequences selected from SEQ ID NO:128-145. In some aspects, both the CDR-L3 and CDR-L2 sequences are derived from a single exemplary V provided in this disclosure. L Sequences. For example, in some respects, both CDR-L3 and CDR-L2 are derived from a single exemplary V selected from SEQ ID NO:204-228. L sequence.

[0161] 2.5.5.CDR-L3+CDR-L1

[0162] In some embodiments, the antibody comprises V L Sequence, the VL The sequence comprises a CDR-L3 sequence, which includes sequences selected from SEQ ID NO:149-166, consisting of sequences selected from SEQ ID NO:149-166, or substantially consisting of sequences selected from SEQ ID NO:149-166; and a CDR-L1 sequence, which includes sequences selected from SEQ ID NO:105-124, consisting of sequences selected from SEQ ID NO:105-124, or substantially consisting of sequences selected from SEQ ID NO:105-124. In some aspects, both the CDR-L3 and CDR-L1 sequences are derived from a single exemplary V provided in this disclosure. L Sequences. For example, in some respects, both CDR-L3 and CDR-L1 are derived from a single exemplary V selected from SEQ ID NO:204-228. L sequence.

[0163] 2.5.6.CDR-L1+CDR-L2

[0164] In some embodiments, the antibody comprises V L Sequence, the V L The sequence comprises a CDR-L1 sequence, which includes sequences selected from SEQ ID NO:105-124, consisting of sequences selected from SEQ ID NO:105-124, or substantially consisting of sequences selected from SEQ ID NO:105-124; and a CDR-L2 sequence, which includes sequences selected from SEQ ID NO:128-145, consisting of sequences selected from SEQ ID NO:128-145, or substantially consisting of sequences selected from SEQ ID NO:128-145. In some aspects, both the CDR-L1 and CDR-L2 sequences are derived from a single exemplary V provided in this disclosure. L Sequences. For example, in some respects, both CDR-L1 and CDR-L2 are derived from a single exemplary V selected from SEQ ID NO:204-228. L sequence.

[0165] 2.5.7.CDR-L1+CDR-L2+CDR-L3

[0166] In some embodiments, the antibody comprises V L Sequence, the V LThe sequence comprises a CDR-L1 sequence comprising sequences selected from SEQ ID NO:105-124, consisting of sequences selected from SEQ ID NO:105-124, or substantially consisting of sequences selected from SEQ ID NO:105-124; a CDR-L2 sequence comprising sequences selected from SEQ ID NO:128-145, consisting of sequences selected from SEQ ID NO:128-145, or substantially consisting of sequences selected from SEQ ID NO:128-145; and a CDR-L3 sequence comprising sequences selected from SEQ ID NO:149-166, consisting of sequences selected from SEQ ID NO:149-166, or substantially consisting of sequences selected from SEQ ID NO:149-166. In some aspects, the CDR-L1, CDR-L2, and CDR-L3 sequences are all derived from a single exemplary V provided in this disclosure. L Sequences. For example, in some respects, CDR-L1, CDR-L2, and CDR-L3 are all derived from a single exemplary V selected from SEQ ID NO:204-228. L sequence.

[0167] In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:105, a CDR-L2 sequence including SEQ ID NO:128, and a CDR-L3 sequence including SEQ ID NO:149. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:106, a CDR-L2 sequence including SEQ ID NO:129, and a CDR-L3 sequence including SEQ ID NO:150. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:107, a CDR-L2 sequence including SEQ ID NO:128, and a CDR-L3 sequence including SEQ ID NO:151. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:108, a CDR-L2 sequence including SEQ ID NO:130, and a CDR-L3 sequence including SEQ ID NO:151. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:109, a CDR-L2 sequence including SEQ ID NO:131, and a CDR-L3 sequence including SEQ ID NO:152. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:107, a CDR-L2 sequence including SEQ ID NO:132, and a CDR-L3 sequence including SEQ ID NO:153. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:110, a CDR-L2 sequence including SEQ ID NO:132, and a CDR-L3 sequence including SEQ ID NO:151. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:111, a CDR-L2 sequence including SEQ ID NO:133, and a CDR-L3 sequence including SEQ ID NO:151. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:105, a CDR-L2 sequence including SEQ ID NO:128, and a CDR-L3 sequence including SEQ ID NO:154. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:112, a CDR-L2 sequence including SEQ ID NO:134, and a CDR-L3 sequence including SEQ ID NO:155.In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:113, a CDR-L2 sequence including SEQ ID NO:135, and a CDR-L3 sequence including SEQ ID NO:156. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:114, a CDR-L2 sequence including SEQ ID NO:136, and a CDR-L3 sequence including SEQ ID NO:157. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:115, a CDR-L2 sequence including SEQ ID NO:135, and a CDR-L3 sequence including SEQ ID NO:157. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:116, a CDR-L2 sequence including SEQ ID NO:128, and a CDR-L3 sequence including SEQ ID NO:155. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:117, a CDR-L2 sequence including SEQ ID NO:137, and a CDR-L3 sequence including SEQ ID NO:155. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:118, a CDR-L2 sequence including SEQ ID NO:137, and a CDR-L3 sequence including SEQ ID NO:158. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:118, a CDR-L2 sequence including SEQ ID NO:138, and a CDR-L3 sequence including SEQ ID NO:155. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:119, a CDR-L2 sequence including SEQ ID NO:139, and a CDR-L3 sequence including SEQ ID NO:159. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:120, a CDR-L2 sequence including SEQ ID NO:140, and a CDR-L3 sequence including SEQ ID NO:160. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:121, a CDR-L2 sequence including SEQ ID NO:141, and a CDR-L3 sequence including SEQ ID NO:161.In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:122, a CDR-L2 sequence including SEQ ID NO:142, and a CDR-L3 sequence including SEQ ID NO:162. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:105, a CDR-L2 sequence including SEQ ID NO:143, and a CDR-L3 sequence including SEQ ID NO:163. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:105, a CDR-L2 sequence including SEQ ID NO:143, and a CDR-L3 sequence including SEQ ID NO:164. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:123, a CDR-L2 sequence including SEQ ID NO:144, and a CDR-L3 sequence including SEQ ID NO:165. In some aspects, the antibody comprises a VL sequence comprising a CDR-L1 sequence including SEQ ID NO:124, a CDR-L2 sequence including SEQ ID NO:145, and a CDR-L3 sequence including SEQ ID NO:166.

[0168] 2.5.8. V containing exemplary CDR-L L Sequence variants

[0169] In some implementations, the V provided herein L The sequences include variants of the exemplary CDR-L3, CDR-L2 and / or CDR-L1 sequences provided in this disclosure.

[0170] In some aspects, a CDR-L3 sequence includes variations of the exemplary CDR-L3 sequences provided in this disclosure, consists of variations of the exemplary CDR-L3 sequences provided in this disclosure, or is substantially composed of variations of the exemplary CDR-L3 sequences provided in this disclosure. In some aspects, a CDR-L3 sequence includes a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L3 sequence provided in this disclosure, consists of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L3 sequence provided in this disclosure, or is substantially composed of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises any exemplary CDR-L3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, consists of any exemplary CDR-L3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary CDR-L3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0171] In some aspects, the CDR-L2 sequence includes variations of the exemplary CDR-L2 sequences provided in this disclosure, consists of variations of the exemplary CDR-L2 sequences provided in this disclosure, or is substantially composed of variations of the exemplary CDR-L2 sequences provided in this disclosure. In some aspects, the CDR-L2 sequence includes sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L2 sequence provided in this disclosure, consists of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L2 sequence provided in this disclosure, or is substantially composed of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L2 sequence provided in this disclosure. In some aspects, the CDR-L2 sequence includes any exemplary CDR-L2 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, constitutes any exemplary CDR-L2 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary CDR-L2 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0172] In some aspects, the CDR-L1 sequence includes variations of the exemplary CDR-L1 sequences provided in this disclosure, consists of variations of the exemplary CDR-L1 sequences provided in this disclosure, or is substantially composed of variations of the exemplary CDR-L1 sequences provided in this disclosure. In some aspects, the CDR-L1 sequence includes sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L1 sequence provided in this disclosure, consists of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L1 sequence provided in this disclosure, or is substantially composed of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L1 sequence provided in this disclosure. In some aspects, the CDR-L1 sequence comprises any exemplary CDR-L1 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, consists of any exemplary CDR-L1 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary CDR-L1 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0173] 2.6.V L sequence

[0174] In some embodiments, the antibody comprises V L Sequence, the V L The sequence includes sequences selected from SEQ ID NO:204-228, consists of sequences selected from SEQ ID NO:204-228, or consists substantially of sequences selected from SEQ ID NO:204-228. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:204, consists of SEQ ID NO:204, or is substantially composed of SEQ ID NO:204. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:205, consists of SEQ ID NO:205, or is substantially composed of SEQ ID NO:205. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:206, consists of SEQ ID NO:206, or is substantially composed of SEQ ID NO:206. In some aspects, the antibody comprises V L Sequence, the V LThe sequence includes SEQ ID NO:207, consists of SEQ ID NO:207, or is substantially composed of SEQ ID NO:207. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:208, consists of SEQ ID NO:208, or is substantially composed of SEQ ID NO:208. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:209, consists of SEQ ID NO:209, or is substantially composed of SEQ ID NO:209. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:210, consists of SEQ ID NO:210, or is substantially composed of SEQ ID NO:210. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:211, consists of SEQ ID NO:211, or is substantially composed of SEQ ID NO:211. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:212, consists of SEQ ID NO:212, or is substantially composed of SEQ ID NO:212. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:213, consists of SEQ ID NO:213, or is substantially composed of SEQ ID NO:213. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:214, consists of SEQ ID NO:214, or is substantially composed of SEQ ID NO:214. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:215, consists of SEQ ID NO:215, or is substantially composed of SEQ ID NO:215. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:216, consists of SEQ ID NO:216, or is substantially composed of SEQ ID NO:216. In some aspects, the antibody comprises V L Sequence, the VL The sequence includes SEQ ID NO:217, consists of SEQ ID NO:217, or is substantially composed of SEQ ID NO:217. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:218, consists of SEQ ID NO:218, or is substantially composed of SEQ ID NO:218. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:219, consists of SEQ ID NO:219, or is substantially composed of SEQ ID NO:219. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:220, consists of SEQ ID NO:220, or is substantially composed of SEQ ID NO:220. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:221, consists of SEQ ID NO:221, or is substantially composed of SEQ ID NO:221. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:222, consists of SEQ ID NO:222, or is substantially composed of SEQ ID NO:222. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:223, consists of SEQ ID NO:223, or is substantially composed of SEQ ID NO:223. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:224, consists of SEQ ID NO:224, or is substantially composed of SEQ ID NO:224. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:225, consists of SEQ ID NO:225, or is substantially composed of SEQ ID NO:225. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:226, consists of SEQ ID NO:226, or is substantially composed of SEQ ID NO:226. In some aspects, the antibody comprises V LSequence, the V L The sequence includes SEQ ID NO:227, consists of SEQ ID NO:227, or is substantially composed of SEQ ID NO:227. In some aspects, the antibody comprises V L Sequence, the V L The sequence includes SEQ ID NO:228, consists of SEQ ID NO:228, or consists essentially of SEQ ID NO:228.

[0175] 2.6.1.V L Sequence variants

[0176] In some implementations, the V provided herein L The sequence includes the exemplary V provided in this disclosure. L Variations of the sequence, as exemplified by V provided in this disclosure L The sequence consists of variants, or is substantially composed of the exemplary V provided in this disclosure. L Composition of sequence variants.

[0177] In some respects, V L The sequence includes the exemplary V provided in this disclosure. L Variations of the sequence, as exemplified by V provided in this disclosure L The sequence consists of variants, or is substantially composed of the exemplary V provided in this disclosure. L The sequence consists of variants. In some respects, V L The sequence includes any exemplary V provided in this disclosure. L A sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity with any of the exemplary V sequences provided in this disclosure. L The sequences consist of sequences having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity, or are substantially composed of sequences identical to any of the exemplary V sequences provided in this disclosure. L The sequence consists of sequences with at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity.

[0178] In some implementation schemes, V L The sequence includes any exemplary V provided in this disclosure. L Sequence, as provided in this disclosure by any exemplary V L The sequence consists of, or is substantially composed of, any exemplary V provided in this disclosure. L Sequence composition, the exemplary V LThe sequence has 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some respects, the amino acid substitutions are conserved.

[0179] 2.7. Regarding

[0180] 2.7.1. CDR-H3–CDR-L3 pair

[0181] In some embodiments, the antibody comprises a CDR-H3 sequence and a CDR-L3 sequence. In some aspects, the CDR-H3 sequence is V H Part of the CDR-L3 sequence and V L Part of it.

[0182] In some respects, the CDR-H3 sequence is a CDR-H3 sequence comprising SEQ ID NO:76-101, consisting of SEQ ID NO:76-101, or substantially consisting of SEQ ID NO:76-101, and the CDR-L3 sequence is a CDR-L3 sequence comprising SEQ ID NO:149-166, consisting of SEQ ID NO:149-166, or substantially consisting of SEQ ID NO:149-166.

[0183] In some aspects, the CDR-H3 sequence is SEQ ID NO:76 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0184] In some aspects, the CDR-H3 sequence is SEQ ID NO:77 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0185] In some aspects, the CDR-H3 sequence is SEQ ID NO:78 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0186] In some aspects, the CDR-H3 sequence is SEQ ID NO:79 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0187] In some aspects, the CDR-H3 sequence is SEQ ID NO:80 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0188] In some aspects, the CDR-H3 sequence is SEQ ID NO:81 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0189] In some aspects, the CDR-H3 sequence is SEQ ID NO:82 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0190] In some aspects, the CDR-H3 sequence is SEQ ID NO:83 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0191] In some aspects, the CDR-H3 sequence is SEQ ID NO:84 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0192] In some aspects, the CDR-H3 sequence is SEQ ID NO:85 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0193] In some aspects, the CDR-H3 sequence is SEQ ID NO:86 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0194] In some aspects, the CDR-H3 sequence is SEQ ID NO:87 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0195] In some aspects, the CDR-H3 sequence is SEQ ID NO:88 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0196] In some aspects, the CDR-H3 sequence is SEQ ID NO:89 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0197] In some aspects, the CDR-H3 sequence is SEQ ID NO:90 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0198] In some aspects, the CDR-H3 sequence is SEQ ID NO:91 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0199] In some aspects, the CDR-H3 sequence is SEQ ID NO:92 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0200] In some aspects, the CDR-H3 sequence is SEQ ID NO:93 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0201] In some aspects, the CDR-H3 sequence is SEQ ID NO:94 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0202] In some aspects, the CDR-H3 sequence is SEQ ID NO:95 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0203] In some aspects, the CDR-H3 sequence is SEQ ID NO:96 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0204] In some aspects, the CDR-H3 sequence is SEQ ID NO:97 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0205] In some aspects, the CDR-H3 sequence is SEQ ID NO:98 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0206] In some aspects, the CDR-H3 sequence is SEQ ID NO:99 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0207] In some aspects, the CDR-H3 sequence is SEQ ID NO:100 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0208] In some aspects, the CDR-H3 sequence is SEQ ID NO:101 and the CDR-L3 sequence is selected from SEQ ID NO:149-166. In some aspects, the CDR-L3 sequence is SEQ ID NO:149. In some aspects, the CDR-L3 sequence is SEQ ID NO:150. In some aspects, the CDR-L3 sequence is SEQ ID NO:151. In some aspects, the CDR-L3 sequence is SEQ ID NO:152. In some aspects, the CDR-L3 sequence is SEQ ID NO:153. In some aspects, the CDR-L3 sequence is SEQ ID NO:154. In some aspects, the CDR-L3 sequence is SEQ ID NO:155. In some aspects, the CDR-L3 sequence is SEQ ID NO:156. In some aspects, the CDR-L3 sequence is SEQ ID NO:157. In some aspects, the CDR-L3 sequence is SEQ ID NO:158. In some aspects, the CDR-L3 sequence is SEQ ID NO:159. In some aspects, the CDR-L3 sequence is SEQ ID NO:160. In some aspects, the CDR-L3 sequence is SEQ ID NO:161. In some aspects, the CDR-L3 sequence is SEQ ID NO:162. In some aspects, the CDR-L3 sequence is SEQ ID NO:163. In some aspects, the CDR-L3 sequence is SEQ ID NO:164. In some aspects, the CDR-L3 sequence is SEQ ID NO:165. In some aspects, the CDR-L3 sequence is SEQ ID NO:166.

[0209] 2.7.1.1. Variants of the CDR-H3-CDR-L3 pair

[0210] In some embodiments, the CDR-H3–CDR-L3 pairs provided herein include variants of the exemplary CDR-H3 and / or CDR-L1 sequences provided in this disclosure.

[0211] In some aspects, the CDR-H3 sequence includes variants of the exemplary CDR-H3 sequence provided in this disclosure, consists of variants of the exemplary CDR-H3 sequence provided in this disclosure, or is substantially composed of variants of the exemplary CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence includes sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-H3 sequence provided in this disclosure, consists of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-H3 sequence provided in this disclosure, or is substantially composed of sequences having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-H3 sequence provided in this disclosure. In some aspects, the CDR-H3 sequence comprises any exemplary CDR-H3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, consists of any exemplary CDR-H3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary CDR-H3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0212] In some aspects, a CDR-L3 sequence includes variations of the exemplary CDR-L3 sequences provided in this disclosure, consists of variations of the exemplary CDR-L3 sequences provided in this disclosure, or is substantially composed of variations of the exemplary CDR-L3 sequences provided in this disclosure. In some aspects, a CDR-L3 sequence includes a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L3 sequence provided in this disclosure, consists of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L3 sequence provided in this disclosure, or is substantially composed of a sequence having at least 70%, 75%, 80%, 85%, 90%, or 95% identity with any exemplary CDR-L3 sequence provided in this disclosure. In some aspects, the CDR-L3 sequence comprises any exemplary CDR-L3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, consists of any exemplary CDR-L3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions, or consists substantially of any exemplary CDR-L3 sequence provided in this disclosure having 1, 2, or 3 amino acid substitutions. In some aspects, the amino acid substitutions are conserved amino acid substitutions.

[0213] 2.7.2.V H -V L right

[0214] In some embodiments, the antibody comprises V H Sequence and V L sequence.

[0215] In some respects, V H The sequence is a V that includes SEQ ID NO:170-200, consists of SEQ ID NO:170-200, or is substantially composed of SEQ ID NO:170-200. H Sequence, and V L The sequence is a V consisting of SEQ ID NO:204-228, or consisting substantially of SEQ ID NO:204-228. L sequence.

[0216] In some respects, V H The sequence is SEQ ID NO:170 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V LThe sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0217] In some respects, V H The sequence is SEQ ID NO:171 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V LThe sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0218] In some respects, V H The sequence is SEQ ID NO:172 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V LThe sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0219] In some respects, V H The sequence is SEQ ID NO:173 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V LThe sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0220] In some respects, V H The sequence is SEQ ID NO:174 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V LThe sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0221] In some respects, V H The sequence is SEQ ID NO:175 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V LThe sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0222] In some respects, V H The sequence is SEQ ID NO:176 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V LThe sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0223] In some respects, V H The sequence is SEQ ID NO:177 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V LThe sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0224] In some respects, V H The sequence is SEQ ID NO:178 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V LThe sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0225] In some respects, V H The sequence is SEQ ID NO:179 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V LThe sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0226] In some respects, V H The sequence is SEQ ID NO:180 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V LThe sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0227] In some respects, V H The sequence is SEQ ID NO:181 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V LThe sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0228] In some respects, V H The sequence is SEQ ID NO:182 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V LThe sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0229] In some respects, V H The sequence is SEQ ID NO:183 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V LThe sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0230] In some respects, V H The sequence is SEQ ID NO:184 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V LThe sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0231] In some respects, V H The sequence is SEQ ID NO:185 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V LThe sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0232] In some respects, V H The sequence is SEQ ID NO:186 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V LThe sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0233] In some respects, V H The sequence is SEQ ID NO:187 and V LThe sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0234] In some respects, V HThe sequence is SEQ ID NO:188 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0235] In some respects, V H The sequence is SEQ ID NO:189 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V LThe sequence is SEQ ID NO:228.

[0236] In some respects, V H The sequence is SEQ ID NO:190 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ED NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V LThe sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0237] In some respects, V H The sequence is SEQ ID NO:191 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V LThe sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0238] In some respects, V H The sequence is SEQ ID NO:192 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V LThe sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0239] In some respects, V H The sequence is SEQ ID NO:193 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V LThe sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0240] In some respects, V H The sequence is SEQ ID NO:194 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V LThe sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0241] In some respects, V H The sequence is SEQ ID NO:195 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V LThe sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0242] In some respects, V H The sequence is SEQ ID NO:196 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V LThe sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0243] In some respects, V H The sequence is SEQ ID NO:197 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, the VL sequence is SEQ ID NO:215. In some respects, V... L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, VL The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0244] In some respects, V H The sequence is SEQ ID NO:198 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V LThe sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0245] In some respects, V H The sequence is SEQ ID NO:199 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V L The sequence is SEQ ID NO:218. In some respects, V LThe sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0246] In some respects, V H The sequence is SEQ ID NO:200 and V L The sequence is selected from SEQ ID NO:204-228. In some respects, V L The sequence is SEQ ID NO:204. In some respects, V L The sequence is SEQ ID NO:205. In some respects, V L The sequence is SEQ ID NO:206. In some respects, V L The sequence is SEQ ID NO:207. In some respects, V L The sequence is SEQ ID NO:208. In some respects, V L The sequence is SEQ ID NO:209. In some respects, V L The sequence is SEQ ID NO:210. In some respects, V L The sequence is SEQ ID NO:211. In some respects, V L The sequence is SEQ ID NO:212. In some respects, V L The sequence is SEQ ID NO:213. In some respects, V L The sequence is SEQ ID NO:214. In some respects, V L The sequence is SEQ ID NO:215. In some respects, V L The sequence is SEQ ID NO:216. In some respects, V L The sequence is SEQ ID NO:217. In some respects, V LThe sequence is SEQ ID NO:218. In some respects, V L The sequence is SEQ ID NO:219. In some respects, V L The sequence is SEQ ID NO:220. In some respects, V L The sequence is SEQ ID NO:221. In some respects, V L The sequence is SEQ ID NO:222. In some respects, V L The sequence is SEQ ID NO:223. In some respects, V L The sequence is SEQ ID NO:224. In some respects, V L The sequence is SEQ ID NO:225. In some respects, V L The sequence is SEQ ID NO:226. In some respects, V L The sequence is SEQ ID NO:227. In some respects, V L The sequence is SEQ ID NO:228.

[0247] 2.7.3.CDR-H1+CDR-H2+CDR-H3+CDR-L1+CDR-L2+CDR-L3

[0248] In some respects, the antibody contains V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence (SEQ ID NO:18), the Kabat CDR-H2 sequence (SEQ ID NO:54), and the Kabat CDR-H3 sequence (SEQ ID NO:76); and a VL sequence comprising the CDR-L1 sequence (SEQ ID NO:105), the CDR-L2 sequence (SEQ ID NO:128), and the CDR-L3 sequence (SEQ ID NO:149). In some aspects, the antibody comprises V... H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:19, the Kabat CDR-H2 sequence of SEQ ID NO:55, and the Kabat CDR-H3 sequence of SEQ ID NO:77; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:20, the Kabat CDR-H2 sequence of SEQ ID NO:56, and the Kabat CDR-H3 sequence of SEQ ID NO:78; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:21, the Kabat CDR-H2 sequence of SEQ ID NO:57, and the Kabat CDR-H3 sequence of SEQ ID NO:79; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:22, the Kabat CDR-H2 sequence of SEQ ID NO:58, and the Kabat CDR-H3 sequence of SEQ ID NO:80; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:21, the Kabat CDR-H2 sequence of SEQ ID NO:57, and the Kabat CDR-H3 sequence of SEQ ID NO:76; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:106, the CDR-L2 sequence of SEQ ID NO:129, and the CDR-L3 sequence of SEQ ID NO:150. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:23, the Kabat CDR-H2 sequence of SEQ ID NO:59, and the Kabat CDR-H3 sequence of SEQ ID NO:76; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:107, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:151. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:23, the Kabat CDR-H2 sequence of SEQ ID NO:60, and the Kabat CDR-H3 sequence of SEQ ID NO:81; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:108, the CDR-L2 sequence of SEQ ID NO:130, and the CDR-L3 sequence of SEQ ID NO:151. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:23, the Kabat CDR-H2 sequence of SEQ ID NO:59, and the Kabat CDR-H3 sequence of SEQ ID NO:82; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:109, the CDR-L2 sequence of SEQ ID NO:131, and the CDR-L3 sequence of SEQ ID NO:152. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:23, the Kabat CDR-H2 sequence of SEQ ID NO:59, and the Kabat CDR-H3 sequence of SEQ ID NO:76; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:107, the CDR-L2 sequence of SEQ ID NO:132, and the CDR-L3 sequence of SEQ ID NO:153. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:23, the Kabat CDR-H2 sequence of SEQ ID NO:59, and the Kabat CDR-H3 sequence of SEQ ID NO:81; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:110, the CDR-L2 sequence of SEQ ID NO:132, and the CDR-L3 sequence of SEQ ID NO:151. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:21, the Kabat CDR-H2 sequence of SEQ ID NO:57, and the Kabat CDR-H3 sequence of SEQ ID NO:83; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:111, the CDR-L2 sequence of SEQ ID NO:133, and the CDR-L3 sequence of SEQ ID NO:151. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:21, the Kabat CDR-H2 sequence of SEQ ID NO:57, and the Kabat CDR-H3 sequence of SEQ ID NO:84; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:24, the Kabat CDR-H2 sequence of SEQ ID NO:61, and the Kabat CDR-H3 sequence of SEQ ID NO:85; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:154. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:24, the Kabat CDR-H2 sequence of SEQ ID NO:61, and the Kabat CDR-H3 sequence of SEQ ID NO:86; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:154. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:25, the Kabat CDR-H2 sequence of SEQ ID NO:62, and the Kabat CDR-H3 sequence of SEQ ID NO:87; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:112, the CDR-L2 sequence of SEQ ID NO:134, and the CDR-L3 sequence of SEQ ID NO:155. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:26, the Kabat CDR-H2 sequence of SEQ ID NO:63, and the Kabat CDR-H3 sequence of SEQ ID NO:88; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:113, the CDR-L2 sequence of SEQ ID NO:135, and the CDR-L3 sequence of SEQ ID NO:156. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:26, the Kabat CDR-H2 sequence of SEQ ID NO:63, and the Kabat CDR-H3 sequence of SEQ ID NO:89; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:114, the CDR-L2 sequence of SEQ ID NO:136, and the CDR-L3 sequence of SEQ ID NO:157. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:25, the Kabat CDR-H2 sequence of SEQ ID NO:63, and the Kabat CDR-H3 sequence of SEQ ID NO:90; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:115, the CDR-L2 sequence of SEQ ID NO:135, and the CDR-L3 sequence of SEQ ID NO:157. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:27, the Kabat CDR-H2 sequence of SEQ ID NO:64, and the Kabat CDR-H3 sequence of SEQ ID NO:90; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:116, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:155. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:28, the Kabat CDR-H2 sequence of SEQ ID NO:62, and the Kabat CDR-H3 sequence of SEQ ID NO:91; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:117, the CDR-L2 sequence of SEQ ID NO:137, and the CDR-L3 sequence of SEQ ID NO:155. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:29, the Kabat CDR-H2 sequence of SEQ ID NO:64, and the Kabat CDR-H3 sequence of SEQ ID NO:92; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:118, the CDR-L2 sequence of SEQ ID NO:137, and the CDR-L3 sequence of SEQ ID NO:158. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:25, the Kabat CDR-H2 sequence of SEQ ID NO:65, and the Kabat CDR-H3 sequence of SEQ ID NO:93; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:118, the CDR-L2 sequence of SEQ ID NO:138, and the CDR-L3 sequence of SEQ ID NO:155. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:30, the Kabat CDR-H2 sequence of SEQ ID NO:66, and the Kabat CDR-H3 sequence of SEQ ID NO:94; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:119, the CDR-L2 sequence of SEQ ID NO:139, and the CDR-L3 sequence of SEQ ID NO:159. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:31, the Kabat CDR-H2 sequence of SEQ ID NO:67, and the Kabat CDR-H3 sequence of SEQ ID NO:95; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:120, the CDR-L2 sequence of SEQ ID NO:140, and the CDR-L3 sequence of SEQ ID NO:160. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:32, the Kabat CDR-H2 sequence of SEQ ID NO:68, and the Kabat CDR-H3 sequence of SEQ ID NO:96; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:121, the CDR-L2 sequence of SEQ ID NO:141, and the CDR-L3 sequence of SEQ ID NO:161. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence including SEQ ID NO:33, the Kabat CDR-H2 sequence including SEQ ID NO:69, and the Kabat CDR-H3 sequence including SEQ ID NO:97; and a VL sequence comprising the CDR-L1 sequence including SEQ ID NO:122, the CDR-L2 sequence including SEQ ID NO:142, and the CDR-L3 sequence including SEQ ID NO:162. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:34, the Kabat CDR-H2 sequence of SEQ ID NO:70, and the Kabat CDR-H3 sequence of SEQ ID NO:98; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:143, and the CDR-L3 sequence of SEQ ID NO:163. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence (SEQ ID NO:18), the Kabat CDR-H2 sequence (SEQ ID NO:54), and the Kabat CDR-H3 sequence (SEQ ID NO:99); and a VL sequence comprising the CDR-L1 sequence (SEQ ID NO:105), the CDR-L2 sequence (SEQ ID NO:143), and the CDR-L3 sequence (SEQ ID NO:164). In some aspects, the antibody comprises V... H Sequence, the V H The sequence comprises the Kabat CDR-H1 sequence of SEQ ID NO:31, the Kabat CDR-H2 sequence of SEQ ID NO:71, and the Kabat CDR-H3 sequence of SEQ ID NO:100; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:123, the CDR-L2 sequence of SEQ ID NO:144, and the CDR-L3 sequence of SEQ ID NO:165. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Kabat CDR-H1 sequence including SEQ ID NO:24, the Kabat CDR-H2 sequence including SEQ ID NO:61, and the Kabat CDR-H3 sequence including SEQ ID NO:101; and the VL sequence comprising the CDR-L1 sequence including SEQ ID NO:124, the CDR-L2 sequence including SEQ ID NO:145, and the CDR-L3 sequence including SEQ ID NO:166.

[0249] In some respects, the antibody contains V H Sequence, the V H The sequence comprises the ChothiaCDR-H1 sequence of SEQ ID NO:1, the ChothiaCDR-H2 sequence of SEQ ID NO:38, and the ChothiaCDR-H3 sequence of SEQ ID NO:76; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:2, the Chothia CDR-H2 sequence of SEQ ID NO:39, and the Chothia CDR-H3 sequence of SEQ ID NO:77; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:2, the Chothia CDR-H2 sequence of SEQ ID NO:40, and the Chothia CDR-H3 sequence of SEQ ID NO:78; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:3, the Chothia CDR-H2 sequence of SEQ ID NO:41, and the Chothia CDR-H3 sequence of SEQ ID NO:79; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:4, the Chothia CDR-H2 sequence of SEQ ID NO:41, and the Chothia CDR-H3 sequence of SEQ ID NO:80; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:3, the Chothia CDR-H2 sequence of SEQ ID NO:41, and the Chothia CDR-H3 sequence of SEQ ID NO:76; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:106, the CDR-L2 sequence of SEQ ID NO:129, and the CDR-L3 sequence of SEQ ID NO:150. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:2, the Chothia CDR-H2 sequence of SEQ ID NO:42, and the Chothia CDR-H3 sequence of SEQ ID NO:76; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:107, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:151. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:2, the Chothia CDR-H2 sequence of SEQ ID NO:43, and the Chothia CDR-H3 sequence of SEQ ID NO:81; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:108, the CDR-L2 sequence of SEQ ID NO:130, and the CDR-L3 sequence of SEQ ID NO:151. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:2, the Chothia CDR-H2 sequence of SEQ ID NO:42, and the Chothia CDR-H3 sequence of SEQ ID NO:82; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:109, the CDR-L2 sequence of SEQ ID NO:131, and the CDR-L3 sequence of SEQ ID NO:152. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:5, the Chothia CDR-H2 sequence of SEQ ID NO:42, and the Chothia CDR-H3 sequence of SEQ ID NO:76; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:107, the CDR-L2 sequence of SEQ ID NO:132, and the CDR-L3 sequence of SEQ ID NO:153. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:2, the Chothia CDR-H2 sequence of SEQ ID NO:42, and the Chothia CDR-H3 sequence of SEQ ID NO:81; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:110, the CDR-L2 sequence of SEQ ID NO:132, and the CDR-L3 sequence of SEQ ID NO:151. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the ChothiaCDR-H1 sequence of SEQ ID NO:3, the ChothiaCDR-H2 sequence of SEQ ID NO:41, and the ChothiaCDR-H3 sequence of SEQ ID NO:83; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:111, the CDR-L2 sequence of SEQ ID NO:133, and the CDR-L3 sequence of SEQ ID NO:151. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:3, the Chothia CDR-H2 sequence of SEQ ID NO:41, and the Chothia CDR-H3 sequence of SEQ ID NO:84; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:149. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:6, the Chothia CDR-H2 sequence of SEQ ID NO:44, and the Chothia CDR-H3 sequence of SEQ ID NO:85; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:154. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:6, the Chothia CDR-H2 sequence of SEQ ID NO:44, and the Chothia CDR-H3 sequence of SEQ ID NO:86; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:154. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:7, the Chothia CDR-H2 sequence of SEQ ID NO:45, and the Chothia CDR-H3 sequence of SEQ ID NO:87; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:112, the CDR-L2 sequence of SEQ ID NO:134, and the CDR-L3 sequence of SEQ ID NO:155. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:8, the Chothia CDR-H2 sequence of SEQ ID NO:44, and the Chothia CDR-H3 sequence of SEQ ID NO:88; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:113, the CDR-L2 sequence of SEQ ID NO:135, and the CDR-L3 sequence of SEQ ID NO:156. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:8, the Chothia CDR-H2 sequence of SEQ ID NO:44, and the Chothia CDR-H3 sequence of SEQ ID NO:89; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:114, the CDR-L2 sequence of SEQ ID NO:136, and the CDR-L3 sequence of SEQ ID NO:157. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:7, the Chothia CDR-H2 sequence of SEQ ID NO:44, and the Chothia CDR-H3 sequence of SEQ ID NO:90; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:115, the CDR-L2 sequence of SEQ ID NO:135, and the CDR-L3 sequence of SEQ ID NO:157. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:9, the Chothia CDR-H2 sequence of SEQ ID NO:44, and the Chothia CDR-H3 sequence of SEQ ID NO:90; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:116, the CDR-L2 sequence of SEQ ID NO:128, and the CDR-L3 sequence of SEQ ID NO:155. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:6, the Chothia CDR-H2 sequence of SEQ ID NO:45, and the Chothia CDR-H3 sequence of SEQ ID NO:91; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:117, the CDR-L2 sequence of SEQ ID NO:137, and the CDR-L3 sequence of SEQ ID NO:155. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence (SEQ ID NO: 8), the Chothia CDR-H2 sequence (SEQ ID NO: 44), and the Chothia CDR-H3 sequence (SEQ ID NO: 92); and a VL sequence comprising the CDR-L1 sequence (SEQ ID NO: 118), the CDR-L2 sequence (SEQ ID NO: 137), and the CDR-L3 sequence (SEQ ID NO: 158). In some aspects, the antibody comprises V... H Sequence, the V H The sequence comprises the ChothiaCDR-H1 sequence of SEQ ID NO:7, the ChothiaCDR-H2 sequence of SEQ ID NO:44, and the ChothiaCDR-H3 sequence of SEQ ID NO:93; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:118, the CDR-L2 sequence of SEQ ID NO:138, and the CDR-L3 sequence of SEQ ID NO:155. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:10, the Chothia CDR-H2 sequence of SEQ ID NO:46, and the Chothia CDR-H3 sequence of SEQ ID NO:94; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:119, the CDR-L2 sequence of SEQ ID NO:139, and the CDR-L3 sequence of SEQ ID NO:159. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:11, the Chothia CDR-H2 sequence of SEQ ID NO:47, and the Chothia CDR-H3 sequence of SEQ ID NO:95; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:120, the CDR-L2 sequence of SEQ ID NO:140, and the CDR-L3 sequence of SEQ ID NO:160. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:12, the Chothia CDR-H2 sequence of SEQ ID NO:48, and the Chothia CDR-H3 sequence of SEQ ID NO:96; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:121, the CDR-L2 sequence of SEQ ID NO:141, and the CDR-L3 sequence of SEQ ID NO:161. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:13, the Chothia CDR-H2 sequence of SEQ ID NO:44, and the Chothia CDR-H3 sequence of SEQ ID NO:97; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:122, the CDR-L2 sequence of SEQ ID NO:142, and the CDR-L3 sequence of SEQ ID NO:162. In some aspects, the antibody comprises V H Sequence, the V HThe sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:14, the Chothia CDR-H2 sequence of SEQ ID NO:49, and the Chothia CDR-H3 sequence of SEQ ID NO:98; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:143, and the CDR-L3 sequence of SEQ ID NO:163. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:1, the Chothia CDR-H2 sequence of SEQ ID NO:38, and the Chothia CDR-H3 sequence of SEQ ID NO:99; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:105, the CDR-L2 sequence of SEQ ID NO:143, and the CDR-L3 sequence of SEQ ID NO:164. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence of SEQ ID NO:11, the Chothia CDR-H2 sequence of SEQ ID NO:50, and the Chothia CDR-H3 sequence of SEQ ID NO:100; and a VL sequence comprising the CDR-L1 sequence of SEQ ID NO:123, the CDR-L2 sequence of SEQ ID NO:144, and the CDR-L3 sequence of SEQ ID NO:165. In some aspects, the antibody comprises V H Sequence, the V H The sequence comprises the Chothia CDR-H1 sequence including SEQ ID NO:6, the Chothia CDR-H2 sequence including SEQ ID NO:44, and the Chothia CDR-H3 sequence including SEQ ID NO:101; and the VL sequence comprising the CDR-L1 sequence including SEQ ID NO:124, the CDR-L2 sequence including SEQ ID NO:145, and the CDR-L3 sequence including SEQ ID NO:166.

[0250] 2.7.3.1.V H –V L variants of

[0251] In some implementations, the V provided herein H –V L For example, the illustrative V provided in this disclosure H and / or V L Variations of the sequence.

[0252] In some respects, V H The sequence includes the exemplary V provided in this disclosure. H Variations of the sequence, as exemplified by V provided in this disclosure H The sequence consists of variants, or is substantially composed of the exemplary V provided in this disclosure. H The sequence consists of variants. In some respects, V H The sequence includes any exemplary V provided in this disclosure. H A sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.1% identity with any of the exemplary V sequences provided in this disclosure. H The sequences consist of sequences having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.1% identity, or are substantially composed of sequences identical to any of the exemplary V sequences provided in this disclosure. H The sequence consists of sequences with at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.1% identity.

[0253] In some implementation schemes, V H The sequence includes any exemplary V provided in this disclosure. H Sequence, as provided in this disclosure by any exemplary V H The sequence consists of, or is substantially composed of, any exemplary V provided in this disclosure. H Sequence composition, the exemplary V H The sequence has 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some respects, the amino acid substitutions are conserved.

[0254] In some respects, V L The sequence includes the exemplary V provided in this disclosure. L Variations of the sequence, as exemplified by V provided in this disclosure L The sequence consists of variants, or is substantially composed of the exemplary V provided in this disclosure. L The sequence consists of variants. In some respects, VL The sequence includes any exemplary V provided in this disclosure. L A sequence having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity with any of the exemplary V sequences provided in this disclosure. L The sequences consist of sequences having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity, or are substantially composed of sequences identical to any of the exemplary V sequences provided in this disclosure. L The sequence consists of sequences with at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.05% identity.

[0255] In some implementation schemes, V L The sequence includes any exemplary V provided in this disclosure. L Sequence, as provided in this disclosure by any exemplary V L The sequence consists of, or is substantially composed of, any exemplary V provided in this disclosure. L Sequence composition, the exemplary V L The sequence has 20 or fewer, 19 or fewer, 18 or fewer, 17 or fewer, 16 or fewer, 15 or fewer, 14 or fewer, 13 or fewer, 12 or fewer, 11 or fewer, 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, 2 or fewer, or 1 or fewer amino acid substitutions. In some respects, the amino acid substitutions are conserved.

[0256] 2.7.4.HC+LC

[0257] In some aspects, the antibody comprises one or more heavy chains consisting of HC sequences and one or more light chains consisting of LC sequences, or consists of one or more heavy chains consisting of HC sequences and one or more light chains consisting of LC sequences. In some aspects, the antibody comprises two identical heavy chains consisting of HC sequences and two identical light chains consisting of LC sequences, or consists of two identical heavy chains consisting of HC sequences and two identical light chains consisting of LC sequences.

[0258] In some aspects, the HC sequence is an HC sequence comprising, consisting of, or substantially consisting of sequences selected from SEQ ID NO:232-262, and the LC sequence is an LC sequence comprising, consisting of, or substantially consisting of sequences selected from SEQ ID NO:300-330. In some embodiments, the HC sequence is an HC sequence comprising sequences selected from SEQ ID NO:232-262, and the LC sequence is an LC sequence comprising sequences selected from SEQ ID NO:300-330. In some embodiments, the HC sequence is an HC sequence comprising sequences selected from SEQ ID NO:266-296, consisting of sequences selected from SEQ ID NO:266-296, or substantially consisting of sequences selected from SEQ ID NO:266-296, and the LC sequence is an LC sequence comprising SEQ ID NO:300-330, consisting of sequences selected from SEQ ID NO:300-330, or substantially consisting of SEQ ID NO:300-330. In some embodiments, the HC sequence is an HC sequence comprising sequences selected from SEQ ID NO:266-296, and the LC sequence is an LC sequence comprising sequences selected from SEQ ID NO:300-330.

[0259] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:232, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0260] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:233, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0261] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:234, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0262] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:235, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0263] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:236, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0264] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:237, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0265] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:238, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0266] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:239, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0267] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:240, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0268] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:241, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0269] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:242, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0270] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:243, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0271] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:244, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0272] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:245, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0273] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:246, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0274] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:247, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0275] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:248, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0276] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:249, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0277] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:250, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0278] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:251, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0279] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:252, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0280] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:253, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0281] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:254, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0282] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:255, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0283] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:256, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0284] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:257, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0285] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:258, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, the LC sequence is SEQ ID NO:302. In some aspects, the LC sequence is SEQ ID NO:303. In some aspects, the LC sequence is SEQ ID NO:304. In some aspects, the LC sequence is SEQ ID NO:305. In some aspects, the LC sequence is SEQ ID NO:306. In some aspects, the LC sequence is SEQ ID NO:307. In some aspects, the LC sequence is SEQ ID NO:308. In some aspects, the LC sequence is SEQ ID NO:309. In some aspects, the LC sequence is SEQ ID NO:310. In some aspects, the LC sequence is SEQ ID NO:311. In some aspects, the LC sequence is SEQ ID NO:312. In some aspects, the LC sequence is SEQ ID NO:313. In some aspects, the LC sequence is SEQ ID NO:314. In some aspects, the LC sequence is SEQ ID NO:315. In some aspects, the LC sequence is SEQ ID NO:316. In some aspects, the LC sequence is SEQ ID NO:317. In some aspects, the LC sequence is SEQ ID NO:318. In some aspects, the LC sequence is SEQ ID NO:319. In some aspects, the LC sequence is SEQ ID NO:320. In some aspects, the LC sequence is SEQ ID NO:321. In some aspects, the LC sequence is SEQ ID NO:322. In some aspects, the LC sequence is SEQ ID NO:323. In some aspects, the LC sequence is SEQ ID NO:324. In some aspects, the LC sequence is SEQ ID NO:325. In some aspects, the LC sequence is SEQ ID NO:326. In some aspects, the LC sequence is SEQ ID NO:327. In some aspects, the LC sequence is SEQ ID NO:328. In some respects, the LC sequence is SEQ ID NO:329. In other respects, the LC sequence is SEQ ID NO:330.

[0286] In some aspects, the HC sequence is the HC sequence consisting of SEQ ID NO:259, and the LC sequence is the LC sequence consisting of sequences selected from SEQ ID NO:300-330. In some aspects, the LC sequence is SEQ ID NO:300. In some aspects, the LC sequence is SEQ ID NO:301. In some aspects, t...

Claims

1. An antibody that specifically binds to human HLA-G (hHLA-G), said antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein: a) The VH includes: i) VHCDR1 consisting of the amino acid sequence shown in SEQ ID NO: 7; VHCDR2 consisting of the amino acid sequence shown in SEQ ID NO: 44; and VHCDR3 consisting of the amino acid sequence shown in SEQ ID NO: 93, wherein the CDRs are numbered according to Chothia; or ii) VHCDR1 consisting of the amino acid sequence shown in SEQ ID NO: 25; VHCDR2 consisting of the amino acid sequence shown in SEQ ID NO: 65; and VHCDR3 consisting of the amino acid sequence shown in SEQ ID NO: 93, wherein the CDRs are numbered according to Kabat; and b) The VL includes: i) VLCDR1 consisting of the amino acid sequence shown in SEQ ID NO: 118; VLCDR2 consisting of the amino acid sequence shown in SEQ ID NO: 138; and VLCDR3 consisting of the amino acid sequence shown in SEQ ID NO: 155, wherein the CDR is numbered according to Chothia and Kabat.

2. The antibody according to claim 1, wherein the VH sequence comprises at least one sequence shown in SEQ ID NO: 192 or at least one sequence having at least 90%, 95% or 99% identity with SEQ ID NO: 192, and / or the VL sequence comprises at least one sequence shown in SEQ ID NO: 220 or at least one sequence having at least 90%, 95% or 99% identity with SEQ ID NO:

220.

3. The antibody according to claim 1, wherein the antibody comprises a VH sequence having at least 90%, at least 95%, or at least 99% identity with the amino acid sequence shown in SEQ ID NO: 192 and a VL sequence having at least 90%, at least 95%, or at least 99% identity with the amino acid sequence shown in SEQ ID NO:

220.

4. The antibody according to any one of claims 1-3, wherein the antibody has one, two, three, four, five, six, or seven of the following characteristics: a) It is a monoclonal antibody; b) It is a human antibody, a humanized antibody, or a chimeric antibody; c) It is a bivalent or multivalent antibody; d) Belongs to IgG1, IgG2, IgG3, IgG4 or IgM type; e) is an antibody fragment that binds to the antigen; f) is a Fab fragment, Fab' fragment, F(ab')2 fragment, or Fv fragment; and / or g) is a single-chain antibody.

5. A pharmaceutical composition comprising the antibody according to any one of claims 1-4.

6. The pharmaceutical composition according to claim 5, further comprising an effective amount of at least one of the following. a) Anti-ILT2 antibody; b) Anti-ILT3 antibody; c) Anti-ILT4 antibody; d) Anti-KIR2DL4 antibody; e) Anti-HLA-E antibody; f) Anti-NKG2A antibody; g) Anti-HLA-F antibody; h) Anti-PD-L1 antibody; i) Anti-PD-1 antibody; j) Anti-CD38 antibody; k) Anti-CD39 antibody; l) Anti-CD73 antibody; m) Anti-A2A receptor antibody; n) Anti-A2B receptor antibody; o) Anti-A2A / A2B dual receptor antibodies or combinations thereof; p) Anti-CD47 antibody; q) Small molecule inhibitors; r) Oncolytic virus.

7. The pharmaceutical composition according to claim 5 or claim 6, further comprising one or two of the following: a) Antibodies against immunosuppressive receptors or ligands, and / or b) Antibodies targeting immune-stimulating receptors or ligands.

8. The antibody of any one of claims 1-3, wherein the antibody binds with a K D binds to a human HLA-G polypeptide or a variant thereof.

9. The antibody of claim 1, comprising a human heavy chain constant region or a fragment or variant thereof and / or a light chain constant region or a fragment or variant thereof, wherein the VH comprises up to 20 conserved amino acid substitutions from the sequence shown in SEQ ID NO: 192 and / or the VL comprises up to 20 conserved amino acid substitutions from the sequence shown in SEQ ID NO:

220.

10. An isolated nucleic acid encoding an antibody according to any one of claims 1-4.

11. A representation vector comprising the nucleic acid according to claim 10.

12. A prokaryotic or eukaryotic host cell comprising the vector according to claim 11.

13. An oncolytic virus encoding the nucleic acid according to claim 10.

14. A method for producing recombinant proteins, comprising the steps of: expressing the nucleic acid according to claim 10 or the expression vector according to claim 11 in prokaryotic or eukaryotic host cells and recovering the protein from the cells or cell culture supernatant.

15. An isolated antibody molecule capable of binding human HLA-G (hHLA-G) comprising a heavy chain and a light chain, the heavy chain comprising one or more molecules having a sequence consisting of one of SEQ ID NO: 254 or SEQ ID NO: 288, and the light chain comprising one or more molecules having a sequence consisting of SEQ ID NO:

322.

16. A separate antibody molecule capable of binding to human HLA-G (hHLA-G), comprising a heavy chain and a light chain, w) The heavy chain comprises one or more molecules, each having a sequence consisting of SEQ ID NO: 254, and the light chain comprises one or more molecules, each having a sequence consisting of SEQ ID NO: 322; or bb) The heavy chain comprises one or more molecules, each having a sequence consisting of SEQ ID NO: 288, and the light chain comprises one or more molecules, each having a sequence consisting of SEQ ID NO:

322.

17. An isolated nucleic acid encoding the antibody of any one of claims 15-16.

Images